

Kingdom of Saudi Arabia
Ministry of Health
National Cancer Registry

Cancer Incidence Report Saudi Arabia 2003

Report prepared by:

Haya S. Al-Eid, BDS, DFE, CTR
Suad Omer Arteh, MA

Reviewed by:

Shouki Bazarbashi, MD
Ali Al-Zahrani, MD, PhD

Foreword

This annual report of the National Cancer Registry (NCR) incorporates cancer incidence data for the entire country. It represents the ongoing effort by the ministry of health, the medical services at ministry of defense, national guard and security forces, college of medicine from all major universities across Saudi Arabia, other health care facilities, physicians, and cancer registrars throughout the country.

This information is presented in the hope that it will assist health care providers, public health officials, voluntary organizations, and concerned citizens in their efforts to prevent and control cancer in Saudi Arabia.

The report summarizes information on new cases of cancer (incidence) for citizens and residents of Saudi Arabia. It also incorporates comparative data from other parts of the world. The report provides information on cancer of all types combined and the 10 most frequently diagnosed cancers in both sexes.

The report represents the cancer incidence in the 10th year of the NCR operation which is considered an important milestone. Cancer incidence trends over the past 10 years will be presented in a separate report that will be devoted mainly for this purpose.

The NCR is committed to preserving the confidentiality of information obtained for medical, educational, research, and statistical purposes. Thus the NCR demands strict confidentiality and the protection of the identity of both cancer patients and reporting sources in registry data. The NCR does not release any identifying information regarding patients, hospitals, or physicians except under the authority of the Ministry of Health.

Shouki Bazarbashi, MD
Chairman

Acknowledgment

First and foremost we would like to acknowledge the Ministry of health for the financial support of the National Cancer Registry (NCR). The production of this report has been made possible by the active cooperation of staffs from hospitals, clinics, pathology laboratories, and others within the Kingdom of Saudi Arabia. The Registry is indebted to all those who have helped in identifying and collecting cases and whose support has been given over many years.

The statistics in this report have been derived from data collected from all sectors of patient care, both governmental and private. We hope the individuals and institutions will find the report useful.

We would also like to acknowledge the relentless support of his Excellency Dr. Hamad Al Manea, Minister of Health and Dr. Mansour Al Hawasi, Deputy Minister of Health for the ongoing operation of the National Cancer Registry. We are in debt for the support given to us by the King Faisal Specialist Hospital and Research Centre administration represented by Dr. Qassim Al Qasabi, Chief Executive Director and Dr. Adnan Ezzat, Executive Director, Medical and Clinical Operation.

Special thanks to our registry staff who worked hard to make this publication possible, and to all previous staff involved in NCR operation for the report period.

Last but not least, we would like to thank the pharmaceutical companies F. Hoffman-La Roche, sanofi-aventis and Novartis Oncology for their generous support for the NCR.

Introduction

This is the seventh incidence report published by the National Cancer Registry of Saudi Arabia. Previous publications include the 1994 Summary Report, 1994-1996 Incidence Report, 1997-1998 Incidence Report, 1999-2000 Incidence Report, 2001 Incidence Report, and 2002 Incidence Report. The current publication covers the year 2003. In the future, publications spanning a more extended period (5-10 years) will have the advantage of presenting more stable incidence rates and time-trends studies.

The structure of this report can be outlined as follows:

Part I Materials and Methods

This part of the report contains information about the background of the National Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II Overview of Cancer Incidence

Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the year 2003. We present these figures and tables mainly by sex and in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2003 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex.

Part III Incidence of Selected-Sites

In this part the incidence of the top ten cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each

selected site the number and the percentage of all newly diagnosed cases for the year 2003, the ASR for each sex, and the specific cancer rank for both sexes. In addition, ASR for the specified cancer among Saudis is compared with ASR among other populations from selected countries.

Part IV Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25-44 age group.

Part V Incidence Tables

Part V contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2003:

- Distribution of cancer cases among Saudis by age group and sex
- Distribution of cancer cases among Non-Saudis by age group and sex
- Cancer Incidence (per 100,000 population) among Saudis by age group and sex
- Cancer Incidence (per 100,000 population) among Non-Saudis by age group and sex
- Age-standardized incidence rate, crude incidence rate and relative frequencies among Saudis by cancer site.

Part VI Appendices

Appendix A: Regional listing of all health care facilities from which cancer cases have been reported. The objective is to receive feedback from facilities that have not been included in order to improve our case-finding and reporting processes.

Appendix B: Names of the members of the Board of Directors.

Appendix C: Data request form which may be copied, filled and submitted to the NCR Main Office.

Appendix D: Copy of the cancer registration abstract form which is completed by cancer registrars for each cancer case.

Table of Contents

Foreword	3
Acknowledgment	3
Introduction	5
 PART I	 9
Background on Saudi Arabia	10
National Cancer Registry	10
Definitions of Statistical Terms	13
 PART II	 15
Cancer in Saudi Arabia 2003	16
Adult Cancers in Saudi Arabia, 2003 (above 14 years)	22
Childhood Cancers in Saudi Arabia 2003 (14 years and below)	24
International Comparison of Age-Standardized Incidence Rates	26
 PART III	 28
Cancer Incidence for Specific Sites, 2003	30
Female Breast (C 50)	31
Colo-rectal (C18-C20)	33
Non-Hodgkin Lymphoma (C82-C85;C96)	35
Thyroid (C 73)	37
Leukemia (C91-C95)	39
Liver (C 22)	41
Skin (Non-Melanoma) (C 44)	43
Stomach (C 16)	45
Hodgkins disease (C 81)	47
Lung (C33-C34)	49
Bladder (C 67)	51
Prostate (C 61)	53
Corpus Uteri (C 55)	55
Ovary (C 56)	57
 PART IV	 60
Cancer Among Non-Saudi Population 2003	62

PART V..... 64

Table 5-1-1 Age Distribution of Cancer Cases among Saudi Males, 2003	65
Table 5-1-2 Age Distribution of Cancer Cases among Saudi Females, 2003	66
Table 5-1-3 Cancer Incidence Cases among Saudi Males by Age Group (per 100,000), 2003.....	67
Table 5-1-4 Cancer Incidence Cases among Saudi Females by Age Group (per 100,000), 2003.....	68
Table 5-3-1 Age Distribution of Cancer Cases among non-Saudi Males, 2003.....	69
Table 5-3-2 Age Distribution of Cancer Cases among non-Saudi Females, 2003	70
Table 5-3-3 Incidence Rates for Cancer Cases among non-Saudi Males by Age Group (per 100,000), 2003	71
Table 5-3-4 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100,000), 2003	72

PART VI 74

APPENDIX A: Reporting Health Care Facilities	75-78
APPENDIX B: Members of NCR Board of Directors	79-80
APPENDIX C: NCR Data Request Form	81
APPENDIX D: Cancer Registration Abstract Form	82

PART I

MATERIALS AND METHODS

Background on Saudi Arabia

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions (Figure I-1).



Figure I.1 Administrative Regions of Saudi Arabia

The Saudi national population for year 2003 was 16,109,198**. Of these, 8,077,700 were males and 8,031,498 were females. The Non-Saudi population in 2003 was 6,009,451**, of these 4,171,663 were males and 1,837,787 females.

Figures I-2 and I-3 show the Saudi and Non-Saudi population pyramids by sex and age group respectively.




Figure I.2 Population Pyramid of Saudis (%) by Sex and Age Group, 2003




Figure I.3 Population Pyramid of non-Saudis (%) by Sex and Age Group, 2003

National Cancer Registry

The National Cancer Registry (NCR) of Saudi Arabia is a population-based registry established in 1992 under the jurisdiction of the Ministry of Health (MOH) by the order of His Excellency the Minister of Health. The NCR commenced reporting cancer cases from 01 January 1994.

Objectives:

The primary goal of the NCR is to define the population-based incidence of cancer in Saudi Arabia. Additional objectives include programs for early detection and cancer screening, as well as cancer research projects.

Organizational Structure:

A Board of Directors was appointed to include representatives from the MOH, King Faisal Specialist Hospital and Research Center (KFSH&RC), and the Medical Services Departments of the Ministry of Defense and Aviation, Ministry of Interior, the National Guard, King Saud University, King Faisal University, King Abdul-Aziz University and King Khalid University. The Board is charged with the responsibility of overseeing the NCR's establishment, defining demographic and cancer-related data to be collected, approving research requests, and reporting findings, as well as disseminating information collected while ensuring the confidentiality of all data reported to the NCR.

* Source: Demographic and Health Indicators for Countries of the East Mediterranean, WHO, Regional Office for the EM, 1999

** Source: Central Department for Statistics (CDS) data, Ministry of Planning, with a 2.5% growth rate for Saudis and a 2.3% growth rate for Non-Saudis (web site <http://www.planning.gov.sa>).

The NCR Main Office, including administrative and technical staff, is located in the premises of the KFSH&RC in Riyadh. Additionally, five regional branches and four hospital-based offices were set up to ensure comprehensive data collection from all over the Kingdom (Figure I-4).

Regional Offices:

- 1 Central Region: King Khalid University Hospital in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.
- 2 Eastern Region: King Fahad Hospital of the University, Al Khobar, covering Dammam, Al Ahsa, and Hafr Al-Batin Health Regions.
- 3 Western Region: King Abdulaziz Hospital and Cancer Center, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.
- 4 Southern Region: King Khalid University, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.
- 5 Madinah/Northern Region: King Fahad Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

Offices at the Medical Service Division or Oncology Department of the following establishment

- 1 Ministry of Defense and Aviation, Armed Forces Hospital, Riyadh
- 2 National Guard, King Fahad Hospital, Riyadh.
- 3 Ministry of Interior, Security Forces Hospital, Riyadh.
- 4 King Faisal Specialist Hospital and Research Centre, Riyadh.
- 5 King Abdul Aziz University Hospital, Jeddah

Each of the NCR offices operates under the supervision of a member of the Board of Directors who is responsible for the daily management of that office. Staffing consists of tumor registrars and secretarial staff.

The NCR Main Office indirectly supervises the regional offices and is responsible for ensuring the accuracy and quality of data collected in all of the regions. Quality control processes include verification of site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares periodic reports for dissemination of information to the medical community, government establishments, international organizations and the media.




Figure I.4 Organizational Chart of the National Cancer Registry of Saudi Arabia

Format

The format of the current report is similar to the previous reports.

Data management

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The NCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients' medical records, based on clinical and/or histopathological diagnosis, by NCR-trained cancer registrars.

The data abstract (see appendix D) includes personal identification (name, ID Number, sex, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the *International Classification of Diseases for Oncology 3rd Edition (ICD-O-3)*, published by the World Health Organization (WHO), 2000.

Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines. However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding of the natural history of cancer. The new guidelines, SEER Summary Stage Manual 2000, is available on the web at: <http://seer.cancer.gov/tools/ssm/>. Cases diagnosed on or after 01 January 2003 are classified according to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now

counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either reportability or definition. However, as with the new staging guidelines, the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.31, cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis.

The computer software programs used for data entry and incidence tables output are *CanReg 4.31*, developed by the International Agency for Research on Cancer, (IARC) Lyon, France.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinicopathological details for the 14 most common cancers among Saudi nationals for the year 2003. For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2003, the age-standardized incidence rate (ASR) per 100,000 population for each sex, and the specific cancer rank in comparison to all cancers for both sexes are presented. Useful international statistics for the specified cancer include the ranking of the cancer worldwide. The source for this information is summarized on page 64.

The relevant data incorporate details for all patients presented over the year 2003. For each cancer there are five figures:

1. An arithmetic line graph represents the age-specific incidence rate (AIR) for all age groups at five-year intervals. The graph is plotted by sex, where applicable.
2. A table lists the percentages of the most common histology sub-types for each specific cancer.
3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown.
4. A bar chart shows regional distribution of ASR for particular cancer across the administrative regions by males and females.
5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

In reviewing the data, its collection and analysis, two qualifying statements can be made:

- a. The number of patients presenting with malignant disease from Riyadh region exceeds the anticipated number per population. The reason for this is that Riyadh has many referral centers providing patients from outside the region with cancer-related care. Many of these patients fail to provide their permanent address, but instead, provide a temporary Riyadh address. This situation is partially resolved through tumor and patient linkage of cases from all regions based on identifiers such as national ID.
- b. As previously noted, the software used in analyzing this report, CanReg 4.31, does not include in situ cases in the incidence tables. These cases were added to the total cancer cases in the overview.

Notification

The data included in this report were abstracted up to June 2005. 2003 incident cases which are identified after this date (late reporting) will be noted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved.

Definitions of Terms

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific age and sex group, divided by the number of midyear population of that age and sex group.

Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

Age Class	Population
0-4	12,000
5-9	10,000
10-14	9,000
15-19	9,000
20-24	8,000
25-29	8,000
30-34	6,000
35-39	6,000
40-44	6,000
45-49	6,000
50-54	5,000
55-59	4,000
60-64	4,000
65-69	3,000
70-74	2,000
75+	2,000
Total	100,000

* Doll R, Payne P, Waterhouse J. Cancer incidence in Five Continents Vol. I. International Union Against Cancer. 1966

Crude Incidence Rate

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population.

Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age.

Cumulative Incidence rate

Cumulative incidence is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-year age intervals. The cumulative rate is five times the sum of the age-specific rates calculated over the five-year age groups.

ICD-10

The World Health Organization's International Classification of Diseases, tenth edition.

ICD-O-3

The World Health Organization's International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Incidence Rate

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided by the population at risk of developing that disease.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Rank

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Relative Frequency

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage

Staging is the grouping of cancer cases into broad categories based on the extent of disease.

PART II
OVERVIEW OF CANCER INCIDENCE
2003

Reported Cancer Incidence Cases in Saudi Arabia, 2003

Between January and December 2003, the total number of cancer incident cases reported to the NCR was 8,840. Overall, cancer was more predominant in men than in women. Cancers affected 4,565 (51.6%) males and 4,275 (48.4%) females, with a male to female ratio of 107:100. 6,644 cases were reported among Saudis, 1,913 among Non-Saudis. The total number of cases excluded from analysis included 283 cases of unknown nationalities. Other exclusions were 156 in situ cases. The current software program CanReg-4 version 4.31, does not include in situ cases in the statistical analysis. Also, 24 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management (see page 12). This puts the total number of exclusions from the analysis as 458 cases. Table 2-1 illustrates the distribution of the cases by sex.

Diagnosis of malignancy was confirmed histologically and/or cytologically in 97.3% of the cases. Clinically confirmed cases were 0.2%; radiologically confirmed cases were 1.8%; and cases confirmed by other methods were 0.6%. The method of diagnosis was unknown for 0.1% of the cases.

As shown on table 2-1, 8,382 cases were analyzed, of which 6,516 (77.7%) were Saudis and 1,866 (22.3%) were Non-Saudis. Among the Saudis, 3,263 (50.1%) were male and 3,253 (49.9 %) were female. The male to female ratio was 100:100. The crude incidence rate (CIR) of all cancers among the Saudi population was 40.4/100,000 (40.5/100,000 among males and 40.3/100,000 among females). The overall age-standardized incidence rate (ASR) for all Saudis with a world standard population reference was 67.5/100,000 (68.7/100,000 in males and 66.3/100,000 in females). For all sites, the age-specific incidence rate (AIR) increased with age for both males and females. After the age of 64 years, the increase was nearly two folds for males compared to females. The mean age at diagnosis was 53 years for men and 48 years for women.

	Saudis			Non-Saudis			Unknown Nationality			All
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Total
Total	3327	3317	6644	1093	820	1913	145	138	283	8840
Invasive	3271	3266	6537	1075	793	1868	144	135	279	8684
In Situ	56	51	107	18	27	45	1	3	4	156
ICD 10 *	8	13	21	1	1	2	0	1	1	24
Analyzed **	3263	3253	6516	1074	792	1866	144	134	278	8382

Table 2.1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex 2003

* ICD-10 conversion failure

** Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

Cancer among Saudis 2003

The total number of cancer cases analyzed among Saudis during the year 2003 were 6,516. Of those cases 51.7% (3,263) were reported among men and 48.3% (3,253) among women.




Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2003










Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex among Saudis, 2003

* 2 Cases (1 male and 1 female) of unknown age are included only in the total as they may not be added to any age group

Cancer	No.	%
Breast	692	10.6
Colo-rectal	566	8.7
Non Hodgkin Lymphoma	521	8.0
Thyroid	428	6.6
Leukemia	423	6.5
Liver	360	5.5
Skin	271	4.2
Stomach	248	3.8
Hodgkin disease	243	3.7
Lung	242	3.7

Table 2.2 Ten Most Common Cancers among Saudis, 2003 (All Ages)




Figure 2.3 Ten Most Common Cancers among Saudis by Sex, 2003




Figure 2.4 Age-Specific Incidence Rates (AIR) for All Cancers among Saudis, 2003

Site	Male						Female					
	No.	%	Crude		ASR		No.	%	Crude		ASR	
			Rate	World	Cumulative Rate				Rate	World	Cumulative Rate	
					0-64	0-74					0-64	0-74
All sites Total	3263	100	40.5	68.7	40.08	103.72	3253	100	40.3	66.3	46.31	87.52
All sites but C - 44	3105	95	38.5	65.1	38.40	97.47	3140	96.5	38.9	63.7	44.97	83.03
Lip	4	0.1	0	0.1	0.05	0.16	5	0.2	0.1	0.1	0.08	0.20
Tongue	28	0.9	0.3	0.6	0.43	0.87	33	1.0	0.4	0.8	0.63	1.01
Mouth	24	0.7	0.3	0.6	0.36	0.99	28	0.9	0.3	0.7	0.31	1.07
Salivary glands	13	0.4	0.2	0.2	0.16	0.25	9	0.3	0.1	0.2	0.19	0.24
Tonsil	5	0.2	0.1	0.1	0.04	0.22	3	0.1	0	0.1	0.02	0.13
Other Oropharynx	0	0.0	0	0	0.00	0.00	0	0.0	-	0	0.00	0.00
Nasopharynx	84	2.6	1	1.7	1.42	1.84	39	1.2	0.5	0.7	0.58	0.79
Hypopharynx	7	0.2	0.1	0.1	0.08	0.22	2	0.1	0	0	0.00	0.12
Pharynx unspec.	3.00	0.09	-	0.10	0.08	0.14	1	0.0	0	0	0.03	0.03
Oesophagus	61	1.9	0.8	1.4	0.69	2.54	48	1.5	0.6	1.1	0.67	1.82
Stomach	173	5.3	2.1	4	2.05	6.73	75	2.3	0.9	1.8	1.01	2.88
Small intestine	13	0.4	0.2	0.3	0.17	0.45	10	0.3	0.1	0.2	0.19	0.35
Colon	174	5.3	2.2	4	2.69	5.89	144	4.4	1.8	3.4	2.53	4.60
Rectum	143	4.4	1.8	3.3	2.32	4.90	105	3.2	1.3	2.5	1.61	3.66
Anus	10	0.3	0.1	0.3	0.26	0.35	10	0.3	0.10	0.2	0.12	0.39
Liver	251	7.7	3.1	6.2	3.33	10.61	109	3.4	1.4	2.8	1.96	4.44
Gallbladder etc.	35	1.1	0.4	0.9	0.55	1.28	56	1.7	0.7	1.4	1.00	2.23
Pancreas	65	2.0	0.8	1.6	0.95	2.54	36	1.1	0.4	0.9	0.45	1.39
Nose, sinuses etc.	10	0.3	0.1	0.2	0.11	0.25	3	0.1	0	0.1	0.01	0.06
Larynx	55	1.7	0.7	1.3	0.87	2.04	4	0.1	0	0.1	0.04	0.04
Trachea,Bronchus,Lung	183	5.6	2.3	4.7	2.85	7.60	59	1.8	0.7	1.4	0.84	2.30
Other Thoracic organs	12	0.4	0.10	0.30	0.18	0.37	10	0.3	0.1	0.1	0.05	0.11
Bone	41	1.3	0.5	0.5	0.35	0.53	37	1.1	0.5	0.4	0.31	0.31
Melanoma of Skin	10	0.3	0.1	0.2	0.06	0.35	7	0.2	0.1	0.2	0.03	0.30
Other Skin	158	4.8	2	3.6	1.68	6.25	113	3.5	1.4	2.6	1.34	4.49
Mesothelioma	5	0.15	0.10	0.10	0.09	0.14	7	0.2	0.10	0.2	0.16	0.21
Kaposi sarcoma	26	0.8	0.3	0.6	0.44	0.87	5	0.2	0.10	0.1	0.08	0.13
Connective,Soft tissue	66	2.0	0.8	1.1	0.78	1.28	53	1.6	0.7	0.8	0.52	0.79
Breast	16	0.5	0.2	0.4	0.24	0.59	676	20.8	8.4	13.9	11.31	16.00
Vulva	-	-	-	-	-	-	6	0.2	0.1	0.1	0.12	0.23
Vagina	-	-	-	-	-	-	0	0.0	0	0	0.00	0.00
Cervix Uteri	-	-	-	-	-	-	87	2.7	1.1	1.9	1.37	2.43
Corpus Uteri	-	-	-	-	-	-	112	3.4	1.4	2.8	1.89	4.15
Uterus unspec.	-	-	-	-	-	-	9	0.3	0.1	0.2	0.21	0.21
Ovary	-	-	-	-	-	-	109	3.4	1.4	2	1.50	2.60
Other Female Genital	-	-	-	-	-	-	5	0.2	0.1	0.1	0.16	0.16
Placenta	-	-	-	-	-	-	6	0.2	0.1	0.1	0.09	0.09
Penis	1	0.0	0	0	0.03	0.03	-	-	-	-	-	-
Prostate	178	5.5	2.2	4.2	0.99	8.51	-	-	-	-	-	-
Testis	38	1.2	0.5	0.5	0.36	0.36	-	-	-	-	-	-
Other male genital	4	0.1	-	0.1	0.05	0.09	-	-	-	-	-	-
Kidney	77	2.4	1	1.6	1.01	2.48	62	1.9	0.8	1.3	1.11	1.43
Renal Pelvis	6	0.18	0.10	0.20	0.15	0.26	2	0.06	-	0.10	0.00	0.11
Ureter	6	0.18	0.10	0.20	0.09	0.28	1	0.03	-	-	0.02	0.02
Bladder	168	5.1	2.1	3.9	2.41	6.16	42	1.3	0.5	1	0.66	1.64
Other Urinary organs	2	0.1	0	0	0.05	0.05	0	0.0	0	0	0.00	0.00
Eye	21	0.6	0.3	0.3	0.13	0.34	15	0.5	0.2	0.2	0.12	0.22
Brain, Nervous system	130	4.0	1.6	2.1	1.43	2.42	81	2.5	1	1.3	0.92	1.53
Thyroid	85	2.6	1.1	1.7	1.19	2.17	343	10.5	4.3	5.7	4.36	6.04
Adrenal gland	14	0.4	0.2	0.2	0.08	0.13	12	0.4	0.1	0.2	0.07	0.12
Other Endocrine	4	0.12	-	-	0.03	0.03	1.00	0.03	-	-	0.01	0.01
Hodgkin disease	139	4.3	1.7	1.8	1.11	1.72	104	3.2	1.3	1.4	0.96	1.40
Non-Hodgkin lymphoma	303	9.3	3.8	5.9	3.15	8.73	218	6.7	2.7	4.5	2.59	6.49
Immunoproliferative dis.	1.00	0.03	-	-	0.03	0.03	-	-	-	-	0.00	0.00
Multiple Myeloma	34	1.0	0.4	0.8	0.50	1.28	12	0.4	0.1	0.3	0.22	0.50
Lymphoid Leukaemia	150	4.6	1.9	2	1.23	1.67	84	2.6	1	1.1	0.64	0.80
Myeloid Leukaemia	85	2.6	1.1	1.4	1.05	1.69	95	2.9	1.2	1.5	1.02	1.73
Leukaemia unspec.	4	0.1	0	0.1	0.01	0.11	5	0.2	0.1	0	0.03	0.03
Other & unspecified	138	4.2	1.7	3.2	1.85	5.08	155	4.8	1.9	3.7	2.31	5.62

Table 2.3 Number, Percentage,ASR,CIR, and Cumulative Rates (per 1000) of New Cases by Primary Site and Sex among Saudis, 2003

Adult Cancers in Saudi Arabia, 2003 (>14 years)

Between January and December 2003, the total number of adult cancer incidence cases reported was 8,165. Overall cancer was slightly more in males than in females. Cancer affected 4,182 (51.2%) males and 3,983 (48.8%) females, with a ratio of

105:100. Of all cases, there were 6,102 Saudis, 1,809 of Non-Saudis and 247 of unknown nationalities. As shown on table 2.4, the total number of analysed cases were 7,748.

	Saudis			Non-Saudis			Unknown Nationality			All
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Total
Total	3025	3084	6109	1035	774	1809	122	125	247	8165
Invasive	2970	3033	6003	1017	747	1764	121	122	243	8010
In-Situ	55	51	106	18	27	45	1	3	4	155
ICD 10*	6	11	17	1	1	2	0	0	0	19
Analyzed**	2964	3022	5986	1016	746	1762	121	122	243	7748

Table 2.4 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex 2003




Figure 2.6 Ten Most Common Cancers among Saudi Adults, 2003

* ICD-10 conversion failure

** Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

Primary Site	Code	Morphology	Male	%	Female	%
Breast	8500	Infiltrating duct carcinoma, NOS	11	68.8	517	76.6
	8520	Lobular carcinoma, NOS	0	0.0	33	4.9
	8010	Carcinoma, NOS	1	6.3	20	3.0
	8523	Infiltrating duct mixed with other types of carcinoma	2	12.5	17	2.5
	8140	Adenocarcinoma, NOS	2	12.5	13	1.9
	8522	Infiltrating duct and lobular carcinoma	0	0.0	14	2.1
	8510	Medullary carcinoma, NOS	0	0.0	12	1.8
	8541	Paget disease and infiltrating duct carcinoma of breast	0	0.0	10	1.5
	8521	Infiltrating ductular carcinoma	0	0.0	7	1.0
		All Others	0	0.0	32	4.7
Colo-rectal	8140	Adenocarcinoma, NOS	227	70.9	181	72.6
	8480	Mucinous adenocarcinoma	31	9.7	21	8.4
	8490	Signet ring cell carcinoma	10	3.4	8	3.2
	8261	Adenocarcinoma in villous adenoma	10	3.1	5	2.0
	8481	Mucin-Producing adenocarcinoma	6	1.9	9	3.6
	8263	Adenocarcinoma in tubulovillous adenoma	9	2.8	4	1.6
	8210	Adenocarcinoma in adenomatous polyp	6	1.9	3	1.2
	8010	Carcinoma, NOS	2	0.6	4	1.6
	8144	Adenocarcinoma, intestinal type	3	1.0	3	1.2
		All Others	11	3.5	11	4.4
NHL	9680	Malignant lymphoma, large B-cell, diffuse, NOS	119	44.9	98	50.5
	9591	Malignant lymphoma, non-Hodgkin, NOS	18	6.8	15	7.7
	9590	Malignant lymphoma, NOS	13	4.9	13	6.7
	9699	Marginal zone B-cell lymphoma, NOS	14	5.3	6	3.1
	9698	Follicular lymphoma, grade 3	10	3.8	8	4.1
	9675	Malignant lymphoma, mixed small and large cell, diffuse	10	3.8	5	2.6
	9690	Follicular lymphoma, NOS	9	3.4	5	2.6
	9670	Malignant lymphoma, small B lymphocytic, NOS	8	3.0	5	2.6
	9714	Anaplastic large cell lymphoma, T cell and Null cell type	2	0.8	10	5.2
	9695	Follicular lymphoma, grade 1	7	2.6	4	2.1
	9691	Follicular lymphoma, grade 2	5	1.9	4	2.1
		All Others	50	18.9	21	10.8
Thyroid	8260	Papillary adenocarcinoma, NOS	50	60.2	200	59.7
	8340	Papillary carcinoma, follicular variant	11	13.3	52	15.5
	8341	Papillary microcarcinoma	6	7.2	30	9.0
	8343	Papillary carcinoma, encapsulated	0	0.0	14	4.2
	8050	Papillary carcinoma, NOS	3	3.6	7	2.1
	8021	Carcinoma, anaplastic, NOS	3	3.6	6	1.8
	8330	Follicular adenocarcinoma, NOS	1	1.2	7	2.1
	8290	Oxyphilic adenocarcinoma	3	3.6	4	1.2
	8510	Medullary carcinoma, NOS	3	3.6	4	1.2
		All Others	3	3.6	11	3.3
Liver	8170	Hepatocellular carcinoma, NOS	213	86.9	79	73.8
	8160	Cholangiocarcinoma	7	2.9	13	12.1
	8000	Neoplasm, malignant	6	2.4	2	1.9
	8010	Carcinoma, NOS	3	1.2	2	1.9
	8162	Klatskin tumor	3	1.2	2	1.9
	8190	Trabecular adenocarcinoma	5	2.0	0	0.0
		All Others	7	3.3	9	8.4
Skin	8090	Basal cell carcinoma, NOS	83	53.2	53	47.3
	8070	Squamous cell carcinoma, NOS	33	21.2	25	22.3
	8071	Squamous cell carcinoma, keratinizing, NOS	10	6.4	7	6.3
	8832	Dermatofibrosarcoma, NOS	6	3.8	7	6.3
	8051	Verrucous carcinoma, NOS	4	2.6	3	2.7
	8091	Multifocal superficial basal cell carcinoma	3	1.9	2	1.8
	8094	Basosquamous carcinoma	3	1.9	2	1.8
	8097	Basal cell carcinoma, nodular	3	1.9	2	1.8
	8410	Sebaceous adenocarcinoma	1	0.6	4	3.6
	8000	Neoplasm, malignant	1	0.6	3	2.7
		All Others	8	5.8	4	3.6
Leukemia	9863	Chronic myeloid leukemia, NOS	18	12.4	25	22.3
	9835	Precursor cell lymphoblastic leukemia, NOS	25	17.2	9	8.0
	9823	B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	21	14.5	8	7.1
	9836	Precursor B-cell lymphoblastic leukemia	14	9.7	10	8.9
	9861	Acute myeloid leukemia, NOS	7	4.8	13	11.6
	9891	Acute monocytic leukemia	6	4.1	13	11.6
	9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	8	5.5	8	7.1
	9867	Acute myelomonocytic leukemia	5	3.4	9	8.0
	9837	Precursor T-cell lymphoblastic leukemia	8	5.5	1	0.9
	9874	Acute myeloid leukemia with maturation	5	3.4	4	3.6
		All Others	27	19.3	12	10.7

Table 2.5 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Adults, 2003

Table 2.5 continued

Primary Site	Code	Morphology	Male	%	Female	%
Stomach	8140	Adenocarcinoma, NOS	81	47.4	34	45.9
	8490	Signet ring cell carcinoma	39	22.8	21	28.4
	8144	Adenocarcinoma, intestinal type	12	7.0	3	4.1
	8145	Carcinoma, diffuse type	12	7.0	1	1.4
	8010	Carcinoma, NOS	4	2.3	4	5.4
	8480	Mucinous adenocarcinoma	6	3.5	1	1.4
	8936	Gastrointestinal stromal sarcoma	4	2.3	1	1.4
		All Others	13	7.6	9	12.2
Lung	8070	Squamous cell carcinoma, NOS	51	27.9	10	16.9
	8140	Adenocarcinoma, NOS	36	19.7	19	32.2
	8041	Small cell carcinoma, NOS	29	15.8	3	5.1
	8010	Carcinoma, NOS	14	7.7	3	5.1
	8046	Non-small cell carcinoma	12	6.6	1	1.7
	8012	Large cell carcinoma, NOS	7	3.8	1	1.7
	8250	Bronchiolo-alveolar adenocarcinoma, NOS	3	1.6	4	6.8
	8071	Squamous cell carcinoma, keratinizing, NOS	5	2.7	0	0.0
		All Others	26	14.2	18	30.5
Bladder	8120	Transitional cell carcinoma, NOS	65	39.2	20	50.0
	8130	Papillary transitional cell carcinoma	68	41.0	11	27.5
	8070	Squamous cell carcinoma, NOS	10	6.0	3.00	7.5
	8120	Transitional cell carcinoma in situ	11	6.6	-	0.0
	8071	Squamous cell carcinoma, keratinizing, NOS	4	2.4	1.00	2.5
		All Others	8	4.8	5.00	12.5
Hodgkins Disease	9663	Hodgkin lymphoma, nodular sclerosis, NOS	32	34.0	49	57.6
	9652	Hodgkin lymphoma, mixed cellularity, NOS	16	17.0	14	16.5
	9667	Hodgkin lymphoma, nodular sclerosis, grade 2	13	13.8	5	5.9
	9650	Hodgkin lymphoma, NOS	8	8.5	7	8.2
	9665	Hodgkin lymphoma, nodular sclerosis, grade 1	8	8.5	5	5.9
	9651	Hodgkin lymphoma, lymphocyte-rich	7	7.4	2	2.4
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	8	8.5	1	1.2
		All Others	2	2.1	2	2.4
Prostate	8140	Adenocarcinoma, NOS	166	93.8	-	-
	8010	Carcinoma, NOS	6	3.4	-	-
	8000	Neoplasm, malignant	3	1.7	-	-
	8070	Squamous cell carcinoma, NOS	1	0.6	-	-
	8120	Transitional cell carcinoma, NOS	1	0.6	-	-
Corpus Uteri	8380	Endometrioid adenocarcinoma, NOS	-	-	58	51.8
	8140	Adenocarcinoma, NOS	-	-	23	20.5
	8260	Papillary adenocarcinoma, NOS	-	-	4	3.6
	8950	Mullerian mixed tumor	-	-	4	3.6
	8890	Leiomyosarcoma, NOS	-	-	3	2.7
	8930	Endometrial stromal sarcoma, NOS	-	-	3	2.7
		All Others	-	-	17	15.2
Ovary	8460	Papillary serous cystadenocarcinoma	-	-	24	23.3
	8140	Adenocarcinoma, NOS	-	-	13	12.6
	8480	Mucinous adenocarcinoma	-	-	9	8.7
	8441	Serous cystadenocarcinoma, NOS	-	-	8	7.8
	8461	Serous surface papillary carcinoma	-	-	8	7.8
	9060	Dysgerminoma	-	-	6	5.8
	8470	Mucinous cystadenocarcinoma, NOS	-	-	5	4.9
	9080	Teratoma, malignant, NOS	-	-	5	4.9
	8010	Carcinoma, NOS	-	-	4	3.9
	8440	Cystadenocarcinoma, NOS	-	-	3	2.9
		All Others	-	-	18	17.5
Cervix uteri	8070	Squamous cell carcinoma, NOS	-	-	30	34.5
	8072	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	-	-	23	26.4
	8071	Squamous cell carcinoma, keratinizing, NOS	-	-	12	13.8
	8140	Adenocarcinoma, NOS	-	-	8	9.2
	8560	Adenosquamous carcinoma	-	-	3	3.4
		All Others	-	-	11	12.6

Childhood Cancers in Saudi Arabia, 2003 (≤ 14 years)

The total incident cases reported among children (0-14 years) between January and December 2003 were 668. This represents 7.6 % of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls. 379 (56.7%) cases were reported among boys and 289 (43.3%) among girls, with a male to female ratio of 131:100. Of all the

cases reported there were 533 Saudis, 104 non-Saudis and 31 of "unknown nationality". Based on table 2-6, the total number of cases analyzed was 632 including 528 (83.5%) Saudis and 104 (16.5%) non-Saudis. Among Saudis, 298(56.4%) were male and 230 (43.6%) were female. The male to female ratio among s Saudis was 129:100.

	Saudis			Non-Saudis			Unknown Nationality			All
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Total
Total	301	232	533	58	46	104	20	11	31	668
Invasive	300	232	532	58	46	104	20	11	31	667
In-Situ	1	0	1	0	0	0	0	0	0	1
ICD 10*	2	2	4	0	0	0	0	1	1	5
Analyzed**	298	230	528	58	46	104	20	10	30	632

Table 2.6 Distribution of Reported Childhood Cancer Cases in Saudi Arabia by Nationality and Sex, 2003

Childhood cancer is very important, not only because of the age of occurrence, but also because 41.7% of the Saudi population is under 15 years of age. In addition to this, recent years have shown a breakthrough for the cure of many childhood cancers. Childhood cancers accounted for 8.1% of all cancer among Saudis.

The leading cancer among Saudi children was leukemia, which accounted for 31.4%, followed by Brain (CNS) then Hodgkins disease and NHL. Figure 2-7 shows the top ten sites by sex and frequency, and table 2-7 shows the number and proportion of the morphological types for the most common types of cancer.




Figure 2.7 Ten Most Common Cancers among Saudi Children by Sex, 2003

* ICD-10 conversion failure

** Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

Primary Site	Code	Morphology	Male	%	Female	%
Leukemia	9836	Precursor B-cell lymphoblastic leukemia	41	43.6	30	41.7
	9835	Precursor cell lymphoblastic leukemia, NOS	27	28.7	21	29.2
	9837	Precursor T-cell lymphoblastic leukemia	8	8.5	3	4.2
	9861	Acute myeloid leukemia, NOS	4	4.3	6	8.3
	9805	Acute biphenotypic leukemia	2	2.1	2	2.8
	9867	Acute myelomonocytic leukemia	2	2.1	1	1.4
	9872	Acute myeloid leukemia, minimal differentiation	1	1.1	2	2.8
		All Others	9	9.6	7	9.7
Brain	9470	Medulloblastoma, NOS	14	31.8	12	41.4
	9380	Glioma, malignant	9	20.5	3	10.3
	9400	Astrocytoma, NOS	3	6.8	3	10.3
	9391	Ependymoma, NOS	2	4.5	3	10.3
	9500	Neuroblastoma, NOS	3	6.8	1	3.4
	8963	Malignant rhabdoid tumor	2	4.5	1	3.4
		All Others	11	25.0	6	20.7
Hodgkins Disease	9663	Hodgkin lymphoma, nodular sclerosis, NOS	25	55.6	10	55.6
	9652	Hodgkin lymphoma, mixed cellularity, NOS	5	11.1	2	11.1
	9665	Hodgkin lymphoma, nodular sclerosis, grade 1	6	13.3	0	0.0
	9651	Hodgkin lymphoma, lymphocyte-rich	4	8.9	1	5.6
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	4	8.9	1	5.6
	9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	1	2.2	1	5.6
		All Others	0	0.0	3	16.7
NHL	9687	Burkitt lymphoma, NOS	20	52.6	10	41.7
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	4	10.5	1	4.2
	9729	Precursor T-cell lymphoblastic lymphoma	1	2.6	4	16.7
	9590	Malignant lymphoma, NOS	2	5.3	2	8.3
	9591	Malignant lymphoma, non-Hodgkin, NOS	3	7.9	1	4.2
	9714	Anaplastic large cell lymphoma, T cell and Null cell type	3	7.9	1	4.2
	9727	Precursor cell lymphoblastic lymphoma, NOS	1	2.6	2	8.3
		All Others	4	10.5	3	12.5
Connective tissue	9500	Neuroblastoma, NOS	3	23.1	6	40.0
	8910	Embryonal rhabdomyosarcoma, NOS	2	15.4	2	13.3
	8920	Alveolar rhabdomyosarcoma	2	15.4	0	0.0
	8900	Rhabdomyosarcoma, NOS	1	7.7	1	6.7
	9490	Ganglioneuroblastoma	0	0.0	2	13.3
		All Others	5	38.5	3	26.7
Eye	9512	Retinoblastoma, undifferentiated	8	57.1	7	70.0
	9510	Retinoblastoma, NOS	5	35.7	2	20.0
	8070	Squamous cell carcinoma, NOS	1	7.1	0	0.0
	9513	Retinoblastoma, diffuse	0	0.0	1	10.0
Bone	9180	Osteosarcoma, NOS	2	28.6	7	46.7
	9260	Ewing sarcoma	2	28.6	7	46.7
	9181	Chondroblastic osteosarcoma	2	28.6	1	6.7
	9473	Primitive neuroectodermal tumor, NOS	1	14.3	0	0.0
Kidney	8960	Nephroblastoma, NOS	11	100.0	9	90.0
	8963	Malignant rhabdoid tumor	0	0.0	1	10.0
Adrenal gland	9500	Neuroblastoma, NOS	8	80.0	5	62.5
	8370	Adrenal cortical carcinoma	1	10.0	2	25.0
	9490	Ganglioneuroblastoma	1	10.0	1	12.5
Liver	8970	Hepatoblastoma	2	40.0	2	100.0
	8170	Hepatocellular carcinoma, NOS	2	40.0	0	0.0
	8910	Embryonal rhabdomyosarcoma, NOS	1	20.0	0	0.0
Thyroid	8260	Papillary adenocarcinoma, NOS	1	100.0	4	66.7
	8330	Follicular adenocarcinoma, NOS	0	0.0	1	16.7
	8340	Papillary carcinoma, follicular variant	0	0.0	1	16.7
Other Thoracic Organs	8002	Malignant tumor, small cell type	-	-	1	16.7
	8581	Thymoma, type A, malignant	-	-	1	16.7
	9490	Ganglioneuroblastoma	-	-	1	16.7
	9500	Neuroblastoma, NOS	-	-	3	50.0
Ovary	9071	Yolk sac tumor	-	-	2	33.3
	9085	Mixed germ cell tumor	-	-	4	66.7
Testis	8910	Embryonal rhabdomyosarcoma, NOS	1	20.0	-	-
	9071	Yolk sac tumor	4	80.0	-	-

Table 2.7 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Children, 2003

International Comparison of Age-Standardized Incidence Rates

Worldwide, it is estimated that around 11 million people developed cancer in 2002. Of these, 53.7% were in developing countries and 46.5% were in developed countries. According to 2002 estimates, the most common cancer site among all men was lung cancer. However; in developed countries prostate was the leading cancer followed by lung,

colo-rectal, and stomach. While in developing countries, lung cancer was first followed by stomach, liver, esophagus and colo-rectal cancers. Among women, breast cancer was the most common followed by colo-rectal, lung and corpus uteri cancers in developed countries. While in the developing countries breast cancer was followed by cancers of the cervix, stomach and lung.




Figure 2.9.A Comparison of ASR* for Saudi Males with Selected Countries**




Figure 2.9.B Comparison of ASR* for Saudi Females with Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

PART III
CANCER INCIDENCE FOR MOST COMMON SITES
2003

Cancer Incidence for Most Common Sites, 2003

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their

relative frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2003.

Cancer	Male	Female	All	%
Breast	16	676	692	10.6
Colo-rectal	317	249	566	8.7
Non-Hodgkin Lymphoma	303	218	521	8.0
Thyroid	85	343	428	6.6
Leukemia	239	184	423	6.5
Liver	251	109	360	5.5
Skin	158	113	271	4.2
Stomach	173	75	248	3.8
Hodgkin disease	139	104	243	3.7
Lung	183	59	242	3.7
Bladder	168	42	210	3.2
Prostate	178	-	178	2.7
Corpus Uteri	-	112	112	1.7
Ovary	-	109	109	1.7
Others	1117	924	1913	29.4
Total	3327	3317	6516	100

Table 3.1 Most Common Cancers among Saudis, 2003

Female Breast (C 50)

There were 676 female breast cancer cases for year 2003. Breast cancer ranked first among females accounting for 20.8% of all newly diagnosed female cancers (3,253). The ASR was 13.9/100,000

for female population. The mean age at diagnosis was 48 years (Range 19-98 years).




Figure 3.1.1 Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia, 2003

ICD-O Code	Morphology	Total	%
8500	Infiltrating duct carcinoma, NOS	518	76.6%
8520	Lobular carcinoma, NOS	33	4.9%
8010	Carcinoma, NOS	20	3.0%
8523	Infiltrating duct mixed with other types of carcinoma	17	2.5%
8522	Infiltrating duct and lobular carcinoma	14	2.1%
8140	Adenocarcinoma, NOS	13	1.9%
8510	Medullary carcinoma, NOS	12	1.8%
8541	Paget disease and infiltrating duct carcinoma of breast	10	1.5%
8521	Infiltrating ductular carcinoma	7	1.0%
All Others		32	4.7%

Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2003




Figure 3.1.2 Stage Distribution of Female Breast Cancer, 2003




Figure 3. I.4 Comparison of ASR* for Female Breast Cancer among Saudi Females with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Colo-rectal (C18-C20)

There were 566 cases of colo-rectal cancer accounting for 8.7% of all newly diagnosed cases in year 2003. This cancer ranked first among male population and third among female population. It affected 317 (56%) males and 249 (44%) females with a male to female ratio of 126:100. The overall ASR was 6.6/100,000. ASR for males was 7.3/100,000 and for females 5.9/100,000.

The mean age at diagnosis was 57 years among males (range 11-90 years) and 57 years among females (range 22-99 years).




Figure 3.2.1 Age-Specific Incidence Rate (AIR) for Colo-rectal Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	227	40%	181	32%
8480	Mucinous adenocarcinoma	31	5.5%	21	3.7%
8490	Signet ring cell carcinoma	11	1.9%	8	1.4%
8261	Adenocarcinoma in villous adenoma	10	1.8%	5	0.9%
8281	Mucin-producing adenocarcinoma	6	1.1%	9	1.6%
8263	Adenocarcinoma in tubulovillous adenoma	9	1.6%	4	0.7%
8210	Adenocarcinoma in adenomatous polyp	6	1.1%	3	0.5%
8010	Carcinoma, NOS	2	0.4%	4	0.7%
	All Others	15	2.7%	14	2.5%

Table 3.2.1 Morphological Distribution of Colo-rectal Cancer in Saudi Arabia, 2003




Figure 3.2.2 Stage Distribution of Colo-rectal Cancer, 2003




Figure 3.2.4 Comparison of ASR* for Colo-rectal Cancer among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Non-Hodgkin Lymphoma (C82-C85; C96)

There were 521 cases of Non-Hodgkin Lymphoma accounting for 8% of all newly diagnosed cancers in year 2003. This cancer ranked second among male population and fourth among female population. It affected 303(51.7%) males and 218(37.3%) females with a male to female ratio of 139:100. The overall ASR was 5.2/100,000. ASR for males was 5.9/100,000 and 4.5/100,000 for females.

The mean age at diagnosis was 49 years among males (range 2-95 years) and 49 years among females (range 1-93 years).




Figure 3.3.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia, 2003

ICD-0-3 Code	Morphology	Male	%	Female	%
9680	Malignant lymphoma, large B-cell, diffuse, NOS	123	23.6%	99	19.0%
9591	Malignant lymphoma, non-Hodgkin, NOS	21	4.0%	16	3.1%
9687	Burkitt lymphoma, NOS	26	5.0%	11	2.1%
9590	Malignant lymphoma, NOS	15	2.9%	15	2.9%
9699	Marginal zone B-cell lymphoma, NOS	14	2.7%	6	1.2%
9698	Follicular lymphoma, grade 3	10	1.9%	8	1.5%
9675	Malignant lymphoma, mixed small and large cell, diffuse	11	2.1%	5	1.0%
9714	Anaplastic large cell lymphoma, T cell and Null cell type	5	1.0%	11	2.1%
9670	Malignant lymphoma, small B lymphocytic, NOS	9	1.7%	5	1.0%
9690	Follicular lymphoma, NOS	9	1.7%	5	1.0%
9695	Follicular lymphoma, grade 1	7	1.3%	4	0.8%
9729	Precursor T-cell lymphoblastic lymphoma	4	0.8%	6	1.2%
9691	Follicular lymphoma, grade 2	5	1.0%	4	0.8%
9702	Mature T-cell lymphoma, NOS	8	1.5%	1	0.2%
9709	Cutaneous T-cell lymphoma, NOS	7	1.3%	1	0.2%
9700	Mycosis fungoides	3	0.6%	4	0.8%
9596	Composite Hodgkin and non-Hodgkin lymphoma	4	0.8%	2	0.4%
9671	Malignant lymphoma, lymphoplasmacytic	3	0.6%	3	0.6%
9673	Mantle cell lymphoma	2	0.4%	3	0.6%
9727	Precursor cell lymphoblastic lymphoma, NOS	3	0.6%	2	0.4%
	All Others	14	2.7%	7	1.3%

Table 3.3.1 Morphological Distribution of NHL in Saudi Arabia, 2003




Figure 3.3.2 Stage Distribution of NHL Cancer, 2003




Figure 3.3.4 Comparison of ASR* for NHL Cancer among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Thyroid (C 73)

There were 428 cases of thyroid cancer for year 2003. This cancer ranked second among female population and eleventh among male population. It affected 85 (19.9%) males and 343 (80.1%) females with a male to female ratio of 25:100. The over all ASR was 3.7/100,000. ASR was 1.7/100,000 for males and 5.7 /100,000 for females.

The mean age at diagnosis was 50 years among males (range 21-80 years) and 39 years among females (range 11-91 years).




Figure 3.4.1 Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
8260	Papillary adenocarcinoma, NOS	51	11.9%	205	47.9%
8340	Papillary carcinoma, follicular variant	11	2.6%	54	12.6%
8341	Papillary microcarcinoma	6	1.4%	30	7.0%
8343	Papillary carcinoma, encapsulated	0	0.0%	14	3.3%
8050	Papillary carcinoma, NOS	3	0.7%	7	1.6%
8021	Carcinoma, anaplastic, NOS	3	0.7%	6	1.4%
8330	Follicular adenocarcinoma, NOS	1	0.2%	8	1.9%
8290	Oxyphilic adenocarcinoma	3	0.7%	4	0.9%
8510	Medullary carcinoma, NOS	3	0.7%	4	0.9%
	All Others	4	0.9%	11	2.3%

Table 3.4.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia, 2003




Figure 3.4.2 Stage Distribution of Thyroid Cancer, 2003




Figure 3.4.4 Comparison of ASR* for Thyroid Cancer among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Leukemia (C91-C95)

There were 423 cases of leukemia accounting for 6.5% of all newly diagnosed cancers in year 2003. This cancer ranked fourth for males and fifth among females and affected 239(56.5%) males and 184(43.5%) females with a male to female ratio of 130:100. The overall ASR was 3/100,000. ASR for males was 3.5/100,000 and 2.6/100,000 for females.

The mean age at diagnosis is 27 years among males (range 0-98 years) and 27 years among females (range 0-91 years).




Figure 3.5.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
9836	Precursor B-cell lymphoblastic leukemia	55	13.0%	40	9.5%
9835	Precursor cell lymphoblastic leukemia, NOS	52	12.3%	30	7.1%
9863	Chronic myeloid leukemia, NOS	18	4.3%	26	6.1%
9861	Acute myeloid leukemia, NOS	11	2.6%	19	4.5%
9823	B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	21	5.0%	8	1.9%
9837	Precursor T-cell lymphoblastic leukemia	16	3.8%	4	0.9%
9891	Acute monocytic leukemia	7	1.7%	13	3.1%
9867	Acute myelomonocytic leukemia	7	1.7%	10	2.4%
9866	Acute promyelocytic leukemia, t(15;17) (q22;q11-12)	8	1.9%	8	1.9%
9874	Acute myeloid leukemia with maturation	7	1.7%	4	0.9%
9871	Acute myeloid leukemia with abnormal marrow eosinophils	5	1.2%	1	0.2%
9872	Acute myeloid leukemia, minimal differentiation	3	0.7%	3	0.7%
9873	Acute myeloid leukemia without maturation	4	0.9%	1	0.2%
All Others		25	5.9%	17	4.0%

Table 3.5.1 Morphological Distribution of Leukemia in Saudi Arabia, 2003




Figure 3.5.3 Comparison of ASR* for Leukemia among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Liver (C 22)

There were 360 cases of liver cancer accounting for 5.5% of all newly diagnosed cases in year 2003. This cancer ranked third in males, and eighth in females and affected 251 (69.7%) males and 109 (30.7%) females with a male to female ratio of 227:100. The overall ASR was 4.5/100,000. ASR was 6.2/100,000 for males and 2.8/100,000 for females.

The mean age at diagnosis was 64 years in males (range 0-98 years) and 62 years in female (range 1-92 years).




Figure 3.6.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
8170	Hepatocellular carcinoma, NOS	216	60.0%	79	21.9%
8160	Cholangiocarcinoma	7	1.9%	13	3.6%
8000	Neoplasm, malignant	6	1.7%	2	0.6%
8010	Carcinoma, NOS	3	0.8%	2	0.6%
8162	Klatskin tumor	3	0.8%	2	0.6%
8190	Trabecular adenocarcinoma	5	1.4%	0	0.0%
8970	Hepatoblastoma	2	0.6%	2	0.6%
	All Others	9	2.5%	9	2.5%

Table 3.6.1 Morphological Distribution of Liver Cancer in Saudi Arabia, 2003




Figure 3.6.2 Stage Distribution of Liver Cancer, 2003




Figure 3.6.4 Comparison of ASR* for Liver Cancer among Saudis with ASR in Selected Countries*

* ASR Per 100,000

** Source for this information is summarized on page 64

Skin (Non-Melanoma) (C 44)

There were 271 cases of skin cancer accounting for 4.2% of all newly diagnosed cases in year 2003. This cancer ranked ninth for males and sixth for females. It affected 158(58.3%) males and 113(41.7%) females with a male to female ratio of 140:100. The overall ASR was 3.1/100,000. ASR was 3.6/100,000 for males and 2.6/100,000 for females.

The mean age at diagnosis was 64 years among males (range 7-98 years) and 62 years among female among female (range 1-97 years).




Figure 3.7.1 Age-Specific Incidence Rate (AIR) for Skin Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
8090	Basal cell carcinoma, NOS	83	30.6%	53	19.6%
8070	Squamous cell carcinoma, NOS	33	12.2%	25	9.2%
8071	Squamous cell carcinoma, keratinizing, NOS	10	3.7%	7	2.6%
8832	Dermatofibrosarcoma, NOS	8	3.0%	8	3.0%
8051	Verrucous carcinoma, NOS	4	1.5%	3	1.1%
8091	Multifocal superficial basal cell carcinoma	3	1.1%	2	0.7%
8094	Basosquamous carcinoma	3	1.1%	2	0.7%
8097	Basal cell carcinoma, nodular	3	1.1%	2	0.7%
8410	Sebaceous adenocarcinoma	1	0.4%	4	1.5%
8000	Neoplasm, malignant	1	0.4%	3	1.1%
	All Others	9	3.3%	4	1.5%

Table 3.7.1 Morphological Distribution of Skin Cancer in Saudi Arabia, 2003




Figure 3.7.2 Stage Distribution of Skin Cancer in Saudi Arabia, 2003




Figure 3.7.4 Comparison of ASR* for Skin Cancer among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Stomach (C 16)

There were 248 cases of stomach cancer accounting for 3.8% of all newly diagnosed cases in year 2003. This cancer ranked seventh among male population and thirteenth among female population. It affected 173 (69.8%) males and 75 (30.2%) females with a male to female ratio of 231:100. The overall ASR was 2.9/100,000. ASR was 4/100,000 for male and 1.8/100,000 for females.

The mean age at diagnosis was 64 years among males (range 4-103 years) and 60 years among female (range 0-83 years).




Figure 3.8.1 Age-Specific Incidence Rate (AIR) for Stomach Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	83	33.5%	34	13.7%
8490	Signet ring cell carcinoma	39	15.7%	22	8.9%
8144	Adenocarcinoma, intestinal type	12	4.8%	3	1.2%
8145	Carcinoma, diffuse type	12	4.8%	1	0.4%
8010	Carcinoma, NOS	4	1.6%	4	1.6%
8480	Mucinous adenocarcinoma	6	2.4%	1	0.4%
8936	Gastrointestinal stromal sarcoma	4	1.6%	1	0.4%
8481	Mucin-producing adenocarcinoma	3	1.2%	1	0.4%
8070	Squamous cell carcinoma, NOS	1	0.4%	2	0.8%
8211	Tubular adenocarcinoma	2	0.8%	1	0.4%
	All Others	7	2.8%	5	2.0%

Table 3.8.1 Morphological Distribution of Stomach Cancer in Saudi Arabia, 2003




Figure 3.8.2 Stage Distribution of Stomach Cancer, 2003




Figure 3.8.4 Comparison of ASR* for Stomach Cancer among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Hodgkins disease (C 81)

There were 243 cases of hodgkin disease cancer accounting for 3.7% of all newly diagnosed cases in year 2003. This cancer ranked tenth among male and female population. It affected 139 (57.2%) males and 104 (42.8%) females with a male to female ratio of 134:100. The overall ASR was 1.6/100,000. ASR was 1.8/100,000 for males and 1.4/100,000 for females.

The mean age at diagnosis was 27 years (range 2-82 years) in males and 29 year in females (range 5-87).




Figure 3.9.1 Age-Specific Incidence Rate (AIR) for Hodgkins disease in Saudi Arabia, 2003

ICD-0-3 Code	Morphology	Male	%	Female	%
9663	Hodgkin lymphoma, nodular sclerosis, NOS	57	23.5%	60	24.7%
9652	Hodgkin lymphoma, mixed cellularity, NOS	21	8.6%	16	6.6%
9667	Hodgkin lymphoma, nodular sclerosis, grade 2	13	5.3%	7	2.9%
9665	Hodgkin lymphoma, nodular sclerosis, grade 1	14	5.8%	5	2.1%
9650	Hodgkin lymphoma, NOS	8	3.3%	8	3.3%
9651	Hodgkin lymphoma, lymphocyte-rich	11	4.5%	3	1.2%
9659	Hodgkin lymphoma, nodular lymphocyte predominance	12	4.9%	2	0.8%
9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	1	0.4%	2	0.8%
All Others		2	0.8%	1	0.4%

Table 3.9.1 Morphological Distribution of Hodgkins disease in Saudi Arabia, 2003




Figure 3.9.2 Stage Distribution of Hodgkins disease, 2003




Figure 3.9.4 Comparison of ASR* for Hodgkins disease among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Lung (C33-C34)

There were 242 cases of lung cancer accounting for 3.7% of all diagnosed cases in year 2003. Lung cancer ranked fifth among male population and fifteenth among female population. It affected 183 (75.6%) males and 59 (24.4%) females with a male to female ratio of 310:100. The overall ASR was 3.1/100,000. ASR was 4.7/100,000 for males and 1.4/100,000 for females.

The mean age at diagnosis was 64 years among males (range 24-98 years) and 61 years among females (range 24-89 years).




Figure 3.10.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
8070	Squamous cell carcinoma, NOS	51	21.1%	10	4.1%
8140	Adenocarcinoma, NOS	36	14.9%	19	7.9%
8041	Small cell carcinoma, NOS	29	12.0%	3	1.2%
8010	Carcinoma, NOS	14	5.8%	3	1.2%
8046	Non-small cell carcinoma	12	5.0%	1	0.4%
8012	Large cell carcinoma, NOS	7	2.9%	1	0.4%
8250	Bronchiolo-alveolar adenocarcinoma, NOS	3	1.2%	4	1.7%
8071	Squamous cell carcinoma, keratinizing, NOS	5	2.1%	0	0.0%
8020	Carcinoma, undifferentiated, NOS	3	1.2%	1	0.4%
8240	Carcinoid tumor, NOS	0	0.0%	4	1.7%
8000	Neoplasm, malignant	1	0.4%	2	0.8%
8033	Pseudosarcomatous carcinoma	1	0.4%	2	0.8%
8249	A typical carcinoid tumor	1	0.4%	2	0.8%
8481	Mucin-producing adenocarcinoma	2	0.8%	1	0.4%
	All Others	18	7.4%	6	2.5%

Table 3.10.1 Morphological Distribution of Lung Cancer in Saudi Arabia, 2003




Figure 3-10-2 Stage Distribution of Lung Cancer, 2003




Figure 3.10.4 Comparison of ASR* for Lung Cancer among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Bladder (C 67)

There were 210 cases of bladder cancer accounting for 3.2% of all newly diagnosed cases in year 2003. This cancer ranked eighth among male population and nineteenth among female population. It affected 168 (80%) males and 42 (20%) females with a male to female ratio of 400:100. The overall ASR was 2.5/100,000. ASR was 3.9/100,000 for males

and 1/100,000 for females. The mean age at diagnosis was 66 among males (range 22-92 years) and 64 among females (range 13-100 years).




Figure 3.11.1 Age-Specific Incidence Rate (AIR) for Bladder Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Male	%	Female	%
8120	Transitional cell carcinoma, NOS	65	31.0%	21	10.0%
8130	Papillary transitional cell carcinoma	70	33.3%	11	5.2%
8070	Squamous cell carcinoma, NOS	10	4.8%	3	1.4%
8120	Transitional cell carcinoma in situ	11	5.2%	0	0.0%
8071	Squamous cell carcinoma, keratinizing, NOS	4	1.9%	1	0.5%
8000	Neoplasm, malignant	1	0.5%	2	1.0%
8010	Carcinoma, NOS	2	1.0%	0	0.0%
8130	Papillary transitional cell carcinoma, non-invasive	2	1.0%	0	0.0%
8140	Adenocarcinoma, NOS	1	0.5%	1	0.5%
	All Others	2	1.0%	3	1.4%

Table 3.11.1 Morphological Distribution of Bladder Cancer in Saudi Arabia, 2003




Figure 3.11.2 Stage Distribution of Bladder Cancer, 2003




Figure 3.I I.4 Comparison of ASR* for Bladder Cancer among Saudis with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Prostate (C 61)

There were 178 cases of prostate cancer accounting for 5.5% of all newly diagnosed cases among males in year 2003. The ASR was 4.2/100,000 among male population. This cancer

ranked eighth among males. The mean age at diagnosis was 72 years (range 44-98 years) .




Figure 3.12.1 Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia, 2003

ICD-O Code	Morphology	Total	%
8140	Adenocarcinoma, NOS	167	93.8%
8010	Carcinoma, NOS	6	3.4%
8000	Neoplasm, malignant	3	1.7%
8070	Squamous cell carcinoma, NOS	1	0.6%
8120	Transitional cell carcinoma, NOS	1	0.6%

Table 3.12.1 Morphological Distribution of Prostate Cancer in Saudi Arabia, 2003




Figure 3.12.2 Stage Distribution of Prostate Cancer, 2003




Figure 3.12.4 Comparison of ASR* for Prostate Cancer among Saudi Males with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Corpus uteri (C 54)

There were 112 cases of corpus uterine cancer among females accounting for 3.4 % of all newly diagnosed cases for females in year 2003. This cancer ranked seventh among female population. The ASR

was 2.8/100,000 for female population. The mean age at diagnosis was 60 years (range 35-94 years).




Figure 3.13.1 Age-Specific Incidence Rate (AIR) for Corpus uterine Cancer in Saudi Arabia, 2003

ICD-O-3 Code	Morphology	Total	%
8380	Endometrioid adenocarcinoma, NOS	58	51.8%
8140	Adenocarcinoma, NOS	23	20.5%
8260	Papillary adenocarcinoma, NOS	4	3.6%
8950	Mullerian mixed tumor	4	3.6%
8890	Leiomyosarcoma, NOS	3	2.7%
8930	Endometrial stromal sarcoma, NOS	3	2.7%
8143	Superficial spreading adenocarcinoma	2	1.8%
8460	Papillary serous cystadenocarcinoma	2	1.8%
8560	Adenosquamous carcinoma	2	1.8%
9100	Choriocarcinoma, NOS	2	1.8%
	All Others	9	8.0%

Table 3.13.1 Morphological Distribution of Corpus uterine Cancer in Saudi Arabia, 2003




Figure 3.13.2 Stage Distribution of Corpus uterine Cancer, 2003




Figure 3.13.4 Comparison of ASR* for Corpus uterine Cancer among Saudi Females with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

Ovary (C 56)

There were 109 cases of ovarian cancer among females accounting for 3.4% of all newly diagnosed cases among females in year 2003. This cancer ranked ninth among female population. The ASR

was 2/100,000 for females. The mean age at diagnosis was 45 years (range 4-86 years).




Figure 3.14.1 Age-Specific Incidence Rate (AIR) for Ovarian Cancer in Saudi Arabia, 2003

ICD-O Code	Morphology	Total	%
8460	Papillary serous cystadenocarcinoma	24	22.0%
8140	Adenocarcinoma, NOS	13	11.9%
8480	Mucinous adenocarcinoma	9	8.3%
8441	Serous cystadenocarcinoma, NOS	8	7.3%
8461	Serous surface papillary carcinoma	8	7.3%
9060	Dysgerminoma	6	5.5%
8470	Mucinous cystadenocarcinoma, NOS	5	4.6%
9080	Teratoma, malignant, NOS	5	4.6%
8010	Carcinoma, NOS	4	3.7%
9071	Yolk sac tumor	4	3.7%
9085	Mixed germ cell tumor	4	3.7%
8440	Cystadenocarcinoma, NOS	3	2.8%
8450	Papillary cystadenocarcinoma, NOS	2	1.8%
8471	Papillary mucinous cystadenocarcinoma	2	1.8%
9364	Peripheral neuroectodermal tumor	2	1.8%
All Others		10	9.2%

Table 3.14.1 Morphological Distribution of Ovarian Cancer in Saudi Arabia, 2003




Figure 3.14.2 Stage Distribution of Ovarian Cancer, 2003




Figure 3.14.4 Comparison of ASR* for Ovarian Cancer among Saudi Females with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 64

*References:

1. Gulf Center for Cancer Registration. 1998-2002 Report. 2006
2. National Cancer Registry. Cancer Incidence in Malaysia 2003. Available from:
http://www.acrm.org.my/ncr/documents/NCR_2nd_Report/Chapter1.pdf
3. Croatian National Cancer Registry. Cancer Incidence in Croatia 2003. Available from:
<http://www.hzjz.hr/cancer/bitn03.htm>
4. Benghazi Cancer Registry. Cancer Incidence in Eastern Libya. 2003
5. Cancer Registry of Slovenia. Cancer Incidence in Slovenia. 2003. Ljubljana 2006.
6. Cancer Registry of Norway. Institute of Population Based Cancer Research. Cancer in Norway 2003. Oslo. 2005
7. Cancer Incidence in Malaysia 2003. Available from:
http://www.acrm.org.my/ncr/documents/NCR_2nd_Report/Chapter1.pdf
8. Welsh Cancer Intelligence & Surveillance Unit. Cancer Incidence 2003 Report. Available from:
<http://www.wales.nhs.uk/sites3/Documents/242/CANCER/INCIDENCE/2003/5F281105/2Epdf>
9. United States Cancer Statistics: 2003 Incidence and Mortality. Available from:
http://www.cdc.gov/cancer/npcr/npcrpdfs/US_Cancer_Statistics_2003_Incidence_and_Mortality.pdf
10. Descriptive Epidemiology Group, IARC. Globocan, 2002. Available from:
<http://www.dep.iarc.fr/>
11. NationalMaster.com.
http://www.nationalmaster.com/graph/hea_bre_can_inc-health-breast-cancer-incidence.
12. Cancer Incidence in Sweden 2003.
<http://www.socialstyrelsen.se/NR/rdonlyres/86E6C7D0-4650-43DA-82DF-FAC11CDB54C5/3019/20044210.pdf>
13. Cancer Incidence and Mortality: 1994-2003
http://www.isdscotland.org/isd/servlet/FileBuffer?namedFile=cancer_incandmort_summary.xls&pContentDispositionType=inline
14. Cancer Research UK.
<http://info.cancerresearchuk.org/cancerstats/types/lung/incidence/>

PART IV
CANCER AMONG NON-SAUDIS
2003

Cancer Among Non- Saudi Population 2003

Between January and December 2003, a total of 1,913 cancer cases were reported among the Non-Saudi population. Forty seven cases were excluded from the analysis including 45 in situ cases and 2 cases that could not be converted from ICD-O-3 to ICD-10. As a result, the total number of cases analyzed were 1866 out of this 1074(57.6%) were males and 792 (42.4%) were females. The male to female ratio was 136:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly,

the pattern of cancer had some significant differences. Those over 60 years represented only 1.8 % and the 20 to 54 age-group represented 72.4% of non-Saudi population. During 2003, approximately 5.6% of all cancers occurred before the age of 15, 28 % occurred between the ages 15 to 40 years, 54.6% were between the ages 41-64, and 12% occurred after the age of 64. The mean age at diagnosis was 47 years in males (range 0-98 years) and 44 years in females (range 0-87 years).

CANCER	All	%
Breast	254	13.6%
Colo-rectal	178	9.5%
Skin	128	6.9%
Leukemia	117	6.3%
Non-Hodgkin Lymphoma	111	5.9%
Thyroid	83	4.4%
Lung	80	4.3%
Stomach	72	3.9%
Bladder	72	3.9%
Brain, Nervous system	55	2.9%

Table 4.1 Ten Most common Cancers among non-Saudis, 2003

Nationality	Male	Female	Total	%
Yemen	213	172	385	20.1
Sudan	132	60	192	10.0
Egypt	100	76	176	9.2
Philippines	59	93	152	7.9
Pakistan	98	43	141	7.4
Gaza Strip (Palestine)	40	45	85	4.4
Bangladesh	80	4	84	4.4
India	61	19	80	4.2
Syrian Arab Republic	48	29	77	4.0
Jordan	30	22	52	2.7
Indonesia	16	27	43	2.2
United States of America	22	17	39	2.0
Bahrain	17	18	35	1.8
Somalia	16	16	32	1.7
United Kingdom	20	11	31	1.6
Other Nationalities	141	168	309	16.2
Total	1093	820	1913	100

Table 4.2 Distribution of Cancer Cases among Different Nationalities in Order of Relative Frequency




Figure 4.1 Ten Most Common Cancer among non-Saudis, 2003




Figure 4.2 Age-Specific Incidence Rate (AIR) for All Cancers among non-Saudis in Saudi Arabia, 2003

PART V

TABLES

Table 5.1.1 Age Distribution of Cancer Cases among Saudi Males, 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.8	0.0	1.3	0.9	0.0	0.1
C01-C02	Tongue	28	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	0.5	0.7	2.8	1.4	2.4	4.0	1.3	3.6	0.3	0.6
C03-C06	Mouth	24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.7	0.5	1.4	4.1	3.0	5.3	4.4	0.3	0.6
C07-C08	Salivary Glands	13	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.5	0.4	0.0	0.0	0.5	0.7	0.8	0.0	0.0	1.8	0.2	0.2
C9	Tonsil	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.0	0.0	2.7	0.1	0.1
C10	Other oropharynx	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	84	0.0	0.0	0.0	0.0	0.6	0.1	0.4	0.7	2.3	2.0	5.2	5.1	7.0	4.9	4.0	2.7	1.8	1.0	1.7
C12-C13	Hypopharynx	7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.0	0.0	2.7	0.1	0.1
C14	Pharynx unspec.	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.0	1.3	0.0	0.0	0.1
C15	Oesophagus	61	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	1.6	1.8	3.5	6.5	6.0	10.6	20.4	0.8	1.4
C16	Stomach	173	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.5	1.5	1.7	2.6	7.9	12.7	13.8	23.9	25.2	44.4	2.1	4.0
C17	Small intestine	13	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.7	1.0	3.2	0.7	1.6	2.0	2.7	0.9	0.2	0.3
C18	Colon	174	0.0	0.0	0.0	0.1	0.1	0.4	0.7	0.5	2.1	3.2	4.9	7.9	11.2	22.7	24.9	18.6	20.4	2.2	4.0
C19-C20	Rectum	143	0.0	0.0	0.0	0.1	0.1	0.3	0.3	0.9	0.8	3.0	5.2	6.5	16.2	13.0	13.9	25.2	12.4	1.8	3.3
C21	Anus	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	1.4	3.2	1.0	0.0	0.9	0.1	0.3
C22	Liver	251	0.0	0.3	0.0	0.2	0.1	0.0	0.3	0.4	1.0	1.2	4.6	6.0	17.6	34.9	37.8	62.4	45.3	3.1	6.2
C23-C24	Gall bladder etc.	35	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.0	3.2	2.8	3.2	7.0	4.0	3.6	0.4	0.9
C25	Pancreas	65	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	0.2	1.3	3.2	7.0	6.5	8.9	10.6	12.4	0.8	1.6
C30-C31	Nose, sinuses, etc.	10	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.9	0.0	0.8	1.0	0.0	1.8	0.1	0.2
C32	Larynx	55	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	1.5	0.7	4.2	5.6	4.9	6.0	12.0	5.3	0.7	1.3
C33-C34	Trachea, Bronchus, Lung	183	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	1.5	3.9	6.9	12.7	30.8	33.8	39.9	21.3	2.3	4.7
C37-C38	Other Thoracic Organs	12	0.0	0.0	0.0	0.1	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.1	0.8	3.0	0.0	0.9	0.1	0.3
C40-C41	Bone	41	0.0	0.0	0.3	0.4	1.0	1.2	0.4	0.4	0.8	0.0	0.0	0.9	0.7	0.8	0.0	2.7	0.9	0.5	0.5
C43	Melanoma of Skin	10	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.0	1.3	4.4	0.1	0.2
C44	Other Skin	158	0.0	0.2	0.0	0.0	0.2	0.3	0.4	0.9	1.5	1.0	2.0	3.2	7.7	16.2	19.9	30.6	40.8	2.0	3.6
C45	Mesothelioma	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.5	0.0	0.8	0.0	0.0	0.9	0.1	0.1
C46	Kaposi sarcoma	26	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.5	0.0	2.3	2.1	3.2	3.0	1.3	4.4	0.3	0.6
C47; C49	Connective, Soft Tissue	66	0.0	0.8	0.4	0.1	0.2	0.7	0.4	0.5	0.6	2.5	1.3	2.8	2.8	2.4	2.0	2.7	5.3	0.8	1.1
C50	Breast	16	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.0	2.1	1.6	3.0	1.3	2.7	0.2	0.4
C60	Penis	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C61	Prostate	178	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.6	4.2	4.9	8.9	36.8	53.1	60.4	2.2	4.2
C62	Testis	38	0.0	0.5	0.0	0.0	0.2	0.4	1.3	0.9	1.3	1.2	0.7	0.0	0.7	0.0	0.0	0.0	0.0	0.5	0.5
C63	Other male genital	4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.9	0.0	0.1
C64	Kidney	77	0.0	0.7	0.4	0.0	0.1	0.0	0.4	0.9	0.6	0.5	1.0	1.8	4.9	8.9	5.0	14.6	9.8	1.0	1.6
C65	Renal pelvis	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	2.4	1.0	1.3	0.0	0.1	0.2
C66	Ureter	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.8	1.0	2.7	0.0	0.1	0.2
C67	Bladder	168	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.9	2.3	3.0	4.3	4.6	14.1	18.7	16.9	30.6	27.5	2.1	3.9
C68	Other urinary organs	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	21	0.0	1.2	0.1	0.1	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.8	1.0	1.3	1.8	0.3	0.3
C70-C72	Brain, Nervous System	130	0.0	1.8	1.3	1.0	0.6	1.2	1.4	1.4	0.6	0.7	1.6	3.2	5.6	8.1	6.0	12.0	1.8	1.6	2.1
C73	Thyroid	85	0.0	0.0	0.0	0.1	0.0	0.4	0.4	1.6	2.5	2.2	2.3	4.2	3.5	6.5	9.9	5.3	4.4	1.1	1.7
C74	Adrenal gland	14	0.0	0.8	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.9	0.2	0.2
C75	Other Endocrine	4	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkin Disease	139	0.0	0.8	1.5	2.0	2.2	1.9	1.1	2.7	1.9	0.7	1.0	1.8	2.1	2.4	3.0	4.0	5.3	1.7	1.8
C82-C85; C96	Non Hodgkin lymphoma	303	0.0	0.8	1.5	1.2	1.4	1.4	2.7	1.8	3.5	3.0	6.2	6.9	14.8	17.8	31.8	39.9	39.9	3.8	5.9
C88	Immunoproliferative dis.	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C90	Multiple Myeloma	34	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.2	0.7	2.3	2.8	3.2	4.0	8.0	3.6	0.4	0.8
C91	Lymphoid Leukaemia	150	0.0	3.7	1.8	1.8	1.9	1.8	1.0	0.5	0.6	0.7	1.6	1.4	2.1	5.7	2.0	4.0	2.7	1.9	2.0
C92-C94	Myeloid Leukaemia	85	0.0	0.5	0.3	0.7	1.1	1.1	0.6	0.7	1.0	1.2	1.6	2.3	4.9	4.9	3.0	8.0	1.8	1.1	1.4
C95	Leukaemia unspec.	4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1
Other	Other & unspecified	138	0.0	0.2	0.0	0.1	0.0	0.1	0.3	0.4	1.5	2.5	1.6	5.1	9.8	15.4	17.9	17.3	29.3	1.7	3.2
All	All Ages Total	3263	1.0	12.2	8.1	8.3	10.3	12.7	12.8	18.5	31.4	37.8	62.4	107.8	192.4	286.8	349.4	465.1	458.3	40.5	68.7
Not C44	All sites but C44	3105	1.0	12.2	7.9	8.3	10.1	12.4	12.4	17.6	29.9	36.8	60.4	104.6	184.7	270.6	329.5	434.5	417.5	38.5	65.1

Table 5.1.2 Age Distribution of Cancer Cases among Saudi Females, 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.1	0.1
C01-C02	Tongue	33	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.8	1.5	1.5	4.0	3.8	3.0	3.6	1.1	0.4	0.8
C03-C06	Mouth	28	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.6	0.0	1.3	2.3	7.1	3.6	4.4	0.3	0.7
C07-C08	Salivary Glands	9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.5	2.0	0.8	0.0	0.0	1.1	0.1	0.2
C9	Tonsil	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.0	0.0	1.1	0.0	0.1
C10	Other oropharynx	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	39	0.0	0.0	0.0	0.1	0.1	0.5	0.4	0.9	1.0	0.8	1.1	1.5	1.3	3.8	3.0	1.2	0.0	0.5	0.7
C12-C13	Hypopharynx	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.1	0.0	0.0
C14	Pharynx unspec.	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C15	Oesophagus	48	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.6	0.3	0.7	3.1	3.4	4.6	6.1	6.0	11.0	0.6	1.1
C16	Stomach	75	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.4	1.1	4.8	1.5	6.0	6.1	12.2	12.1	13.2	0.9	1.8
C17	Small intestine	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.4	0.0	2.0	0.8	1.0	1.2	1.1	0.1	0.2
C18	Colon	144	0.0	0.0	0.0	0.0	0.0	0.3	0.3	1.4	1.2	4.7	4.4	10.3	13.4	14.5	15.2	10.9	15.4	1.8	3.4
C19-C20	Rectum	105	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	1.0	2.2	4.4	7.7	6.0	9.9	9.1	12.1	19.8	1.3	2.5
C21	Anus	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.8	3.0	1.2	1.1	0.1	0.1	0.1
C22	Liver	109	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.2	1.1	1.5	3.6	8.7	23.7	15.2	15.7	18.7	1.4	2.8
C23-C24	Gall bladder etc.	56	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.6	1.5	2.1	6.0	9.2	6.1	9.7	8.8	0.7	1.4
C25	Pancreas	36	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.7	4.1	3.4	0.0	5.1	6.0	7.7	0.4	0.9
C30-C31	Nose, sinuses, etc.	3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1
C32	Larynx	4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C33-C34	Trachea, Bronchus, Lung	59	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.2	1.4	2.2	1.5	4.0	6.9	6.1	12.1	11.0	0.7	1.4
C37-C38	Other Thoracic Organs	10	0.0	0.4	0.0	0.2	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.1
C40-C41	Bone	37	0.0	0.0	0.6	0.7	0.8	0.3	0.6	0.4	0.4	0.3	0.7	0.5	0.0	0.8	0.0	0.0	0.0	0.5	0.4
C43	Melanoma of Skin	7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.0	0.0	4.4	0.1	0.2
C44	Other Skin	113	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.4	2.1	0.8	3.7	3.6	6.0	9.9	11.2	25.4	26.4	1.4	2.6
C45	Mesothelioma	7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	1.0	0.0	1.5	1.0	0.0	0.0	0.1	0.2
C46	Kaposi sarcoma	5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.5	0.0	0.8	1.0	0.0	0.0	0.1	0.1
C47; C49	Connective, Soft Tissue	53	0.0	1.3	0.0	0.2	0.8	0.4	0.3	0.9	0.8	0.6	1.5	2.1	0.7	0.8	1.0	0.0	4.4	0.7	0.8
C50	Breast	676	0.0	0.0	0.0	0.0	0.1	1.3	3.2	10.4	18.1	27.5	44.4	41.7	37.5	42.0	34.5	33.9	25.3	8.4	13.9
C51	Vulva	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.3	0.8	0.0	0.0	2.2	0.1	0.1
C52	Vagina	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C53	Cervix Uteri	87	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.9	1.9	3.6	4.8	5.7	4.7	5.3	8.1	10.9	2.2	1.1	1.9
C54	Corpus Uteri	112	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	2.8	5.2	4.6	12.1	12.2	16.2	18.1	11.0	1.4	2.8
C55	Uterus Unspec.	9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.4	1.5	0.7	0.8	0.0	0.0	0.0	0.1	0.2
C56	Ovary	109	0.0	0.1	0.2	0.3	0.8	0.9	0.7	1.6	2.3	2.5	3.7	3.1	10.7	3.1	4.1	14.5	3.3	1.4	2.0
C57	Other Female Genital	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.7	1.5	0.0	0.0	0.0	0.1	0.1
C58	Placenta	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.3	0.4	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.1
C64	Kidney	62	0.0	0.8	0.2	0.0	0.1	0.1	0.1	0.5	1.2	1.7	1.8	2.6	5.4	7.6	3.0	1.2	2.2	0.8	1.3
C65	Renal pelvis	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.1	0.0	0.1
C66	Ureter	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Bladder	42	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.4	0.3	0.4	2.6	4.0	5.3	5.1	2.4	12.1	0.5	1.0
C68	Other urinary organs	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	15	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.8	1.0	0.0	1.1	0.2	0.2
C70-C72	Brain, Nervous System	81	0.0	0.7	1.1	0.9	0.8	0.1	0.3	0.4	0.8	1.4	1.8	1.5	4.0	4.6	4.1	4.8	3.3	1.0	1.3
C73	Thyroid	343	1.0	0.0	0.1	0.4	2.3	4.6	4.2	8.9	9.5	11.3	9.2	14.4	10.7	11.5	7.1	13.3	13.2	4.3	5.7
C74	Adrenal gland	12	0.0	0.4	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.1	0.2
C75	Other Endocrine	1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkin Disease	104	0.0	0.0	0.6	1.1	2.4	2.7	1.2	1.1	1.0	0.3	1.8	0.5	3.4	3.1	2.0	1.2	5.5	1.3	1.4
C82-C85; C96	Non Hodgkin lymphoma	218	0.0	1.1	0.2	1.0	1.0	1.3	1.2	2.0	1.4	3.3	5.9	8.2	6.0	19.1	26.4	24.2	27.5	2.7	4.5
C88	Immunoproliferative dis.	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C90	Multiple Myeloma	12	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.7	3.1	2.0	2.4	1.1	0.1	0.3
C91	Lymphoid Leukaemia	84	0.0	3.0	1.8	0.4	0.8	0.4	0.6	0.2	0.4	0.6	0.7	1.0	1.3	1.5	1.0	1.2	1.1	1.0	1.1
C92-C94	Myeloid Leukaemia	95	0.0	0.4	0.4	0.7	1.3	1.3	1.3	2.0	1.0	3.3	1.1	2.6	2.7	3.1	5.1	4.8	4.4	1.2	1.5
C95	Leukaemia unspec.	5	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
Other	Other & unspecified	155	0.0	0.3	0.0	0.1	0.5	0.3	0.3	0.5	0.6	3.3	3.7	6.2	12.1	18.3	19.3	19.3	27.5	1.9	3.7
All	All Ages Total	3253	1.0	9.9	5.6	6.5	12.2	15.8	16.3	35.9	49.3	79.9	117.1	144.8	188.2	244.7	250.4	277.8	295.9	40.3	66.3
Not C44	All sites but C44	3140	1.0	9.8	5.6	6.5	12.2	15.7	16.2	35.5	47.2	79.1	113.4	141.2	182.2	234.8	239.2	252.4	269.5	38.9	63.7

Table 5.1.3 Cancer Incidence Cases among Saudi Males by Age Group (per 100,000), 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.8	0.0	1.3	0.9	0.0	0.1
C01-C02	Tongue	28	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	0.5	0.7	2.8	1.4	2.4	4.0	1.3	3.6	0.6
C03-C06	Mouth	24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.7	0.5	1.4	4.1	3.0	5.3	4.4	0.3
C07-C08	Salivary Glands	13	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.5	0.4	0.0	0.0	0.5	0.7	0.8	0.0	0.0	1.8	0.2
C9	Tonsil	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.0	1.0	2.7	0.1	0.1
C10	Other oropharynx	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	84	0.0	0.0	0.0	0.0	0.6	0.1	0.4	0.7	2.3	2.0	5.2	5.1	7.0	4.9	4.0	2.7	1.8	1.0	1.7
C12-C13	Hypopharynx	7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.8	0.0	0.0	2.7	0.1	0.1
C14	Pharynx unspec.	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.0	1.3	0.0	0.0	0.1
C15	Oesophagus	61	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	1.6	1.8	3.5	6.5	6.0	10.6	20.4	0.8	1.4
C16	Stomach	173	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.5	1.5	1.7	2.6	7.9	12.7	13.8	23.9	25.2	44.4	2.1	4.0
C17	Small intestine	13	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.7	0.0	0.0	0.7	1.6	2.0	2.7	0.9	0.2	0.3
C18	Colon	174	0.0	0.0	0.1	0.1	0.4	0.7	0.5	2.1	3.2	4.9	7.9	11.2	22.7	24.9	18.6	20.4	2.2	4.0	2.2
C19-C20	Rectum	143	0.0	0.0	0.0	0.1	0.1	0.3	0.3	0.9	0.8	3.0	5.2	6.5	16.2	13.0	13.9	25.2	12.4	1.8	3.3
C21	Anus	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	1.4	3.2	1.0	0.0	0.9	0.1	0.3
C22	Liver	251	0.0	0.3	0.0	0.2	0.1	0.0	0.3	0.4	1.0	1.2	4.6	6.0	17.6	34.9	37.8	62.4	45.3	3.1	6.2
C23-C24	Gall bladder etc.	35	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.0	3.2	2.8	3.2	7.0	4.0	3.6	0.4	0.9
C25	Pancreas	65	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	0.2	1.3	3.2	7.0	6.5	8.9	10.6	12.4	0.8	1.6
C30-C31	Nose, sinuses, etc.	10	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.9	0.0	0.8	1.0	0.0	1.8	0.1	0.2
C32	Larynx	55	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	1.5	0.7	4.2	5.6	4.9	6.0	12.0	5.3	0.7	1.3	0.7
C33-C34	Trachea, Bronchus, Lung	183	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	1.5	3.9	6.9	12.7	30.8	33.8	39.9	21.3	2.3	4.7
C37-C38	Other Thoracic Organs	12	0.0	0.0	0.0	0.1	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.1	0.8	3.0	0.0	0.9	0.1	0.3
C40-C41	Bone	41	0.0	0.0	0.3	0.4	1.0	1.2	0.4	0.8	0.0	0.0	0.0	0.9	0.7	0.8	0.0	2.7	0.9	0.5	0.5
C43	Melanoma of Skin	10	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.0	1.3	4.4	0.1	0.2
C44	Other Skin	158	0.0	0.0	0.2	0.0	0.2	0.3	0.4	0.9	1.5	2.0	3.2	7.7	16.2	19.9	30.6	40.8	2.0	3.6	0.1
C45	Mesothelioma	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.5	0.0	0.8	0.0	0.0	0.9	0.1	0.1
C46	Kaposi sarcoma	26	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.5	0.0	2.3	2.1	3.2	3.0	1.3	4.4	0.3	0.6
C47; C49	Connective, Soft Tissue	66	0.0	0.8	0.4	0.1	0.2	0.7	0.4	0.5	0.6	2.5	1.3	2.8	2.8	2.4	2.0	2.7	5.3	0.8	1.1
C50	Breast	16	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.0	2.1	1.6	3.0	1.3	2.7	0.2	0.4
C60	Penis	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C61	Prostate	178	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.6	4.2	4.9	8.9	36.8	53.1	60.4	2.2	4.2
C62	Testis	38	0.0	0.5	0.0	0.0	0.2	0.4	1.3	0.9	1.3	1.2	0.7	0.0	0.7	0.0	0.0	0.0	0.0	0.5	0.5
C63	Other male genital	4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.9	0.0	0.1
C64	Kidney	77	0.0	0.7	0.4	0.0	0.1	0.0	0.4	0.9	0.6	0.5	1.0	1.8	4.9	8.9	5.0	14.6	9.8	1.0	1.6
C65	Renal pelvis	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	2.4	1.0	1.3	0.0	0.1	0.2
C66	Ureter	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.8	1.0	2.7	0.0	0.1	0.2
C67	Bladder	168	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	14.1	18.7	16.9	30.6	27.5	2.1	3.9
C68	Other urinary organs	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	21	0.0	1.2	0.1	0.1	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.8	1.0	1.3	1.8	0.3	0.3
C70-C72	Brain, Nervous System	130	0.0	1.8	1.3	1.0	0.6	1.2	1.4	1.4	0.6	0.7	1.6	3.2	5.6	8.1	6.0	12.0	1.8	1.6	2.1
C73	Thyroid	85	0.0	0.0	0.0	0.1	0.0	0.4	0.4	1.6	2.5	2.2	2.3	4.2	3.5	6.5	9.9	5.3	4.4	1.1	1.7
C74	Adrenal gland	14	0.0	0.8	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.9	0.2	0.2
C75	Other Endocrine	4	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkin Disease	139	0.0	0.8	1.5	2.0	2.2	1.9	1.1	2.7	1.9	0.7	1.0	1.8	2.1	2.4	3.0	4.0	5.3	1.7	1.8
C82-C85; C96	Non Hodgkin lymphoma	303	0.0	0.8	1.5	1.2	1.4	1.4	2.7	1.8	3.5	3.0	6.2	6.9	14.8	17.8	31.8	39.9	39.9	3.8	5.9
C88	Immunoproliferative dis.	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C90	Multiple Myeloma	34	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.2	0.7	2.3	2.8	3.2	4.0	8.0	3.6	0.4	0.8
C91	Lymphoid Leukaemia	150	0.0	3.7	1.8	1.8	1.9	1.8	1.0	0.5	0.6	0.7	1.6	1.4	2.1	5.7	2.0	4.0	2.7	1.9	2.0
C92-C94	Myeloid Leukaemia	85	0.0	0.5	0.3	0.7	1.1	1.1	0.6	0.7	1.0	1.2	1.6	2.3	4.9	4.9	3.0	8.0	1.8	1.1	1.4
C95	Leukaemia unspec.	4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1
Other	Other & unspecified	138	0.0	0.2	0.0	0.1	0.0	0.1	0.3	0.4	1.5	2.5	1.6	5.1	9.8	15.4	17.9	17.3	29.3	1.7	3.2
All	All Ages Total	3263	1.0	12.2	8.1	8.3	10.3	12.7	12.8	18.5	31.4	37.8	62.4	107.8	192.4	286.8	349.4	465.1	458.3	40.5	68.7
Not C44	All sites but C44	3105	1.0	12.2	7.9	8.3	10.1	12.4	12.4	17.6	29.9	36.8	60.4	104.6	184.7	270.6	329.5	434.5	417.5	38.5	65.1

Table 5.1.4 Cancer Incidence Cases among Saudi Females by Age Group (per 100,000), 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.3	0.0	2.4	0.0	0.1	0.1
C01-C02	Tongue	33	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.8	0.8	1.5	1.5	4.0	3.8	3.0	3.6	1.1	0.4	0.8
C03-C06	Mouth	28	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.6	0.0	1.5	2.3	7.1	7.1	3.6	4.4	0.3	0.7
C07-C08	Salivary Glands	9	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.5	2.0	0.8	0.0	0.0	1.1	0.1	0.2
C9	Tonsil	3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.0	0.0	1.1	0.0	0.1
C10	Other oropharynx	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C11	Nasopharynx	39	0.0	0.0	0.0	0.1	0.1	0.5	0.4	0.9	1.0	0.8	1.1	1.5	1.3	3.8	3.0	1.2	0.0	0.5	0.7
C12-C13	Hypopharynx	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.1	0.0	0.0
C14	Pharynx unspec.	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C15	Oesophagus	48	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.6	0.3	0.7	3.1	3.4	4.6	6.1	6.0	11.0	0.6	1.1
C16	Stomach	75	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.4	1.1	4.8	1.5	6.0	6.1	12.2	12.1	13.2	0.9	1.8
C17	Small intestine	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.4	0.0	2.0	0.8	1.0	1.2	1.1	0.1	0.2
C18	Colon	144	0.0	0.0	0.0	0.0	0.0	0.3	0.3	1.4	1.2	4.7	4.4	10.3	13.4	14.5	15.2	10.9	15.4	1.8	3.4
C19-C20	Rectum	105	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	1.0	2.2	4.4	7.7	6.0	9.9	9.1	12.1	19.8	1.3	2.5
C21	Anus	10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.7	0.8	3.0	1.2	1.1	0.1	0.2
C22	Liver	109	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.2	1.1	1.5	3.6	8.7	23.7	15.2	15.7	18.7	1.4	2.8
C23-C24	Gall bladder etc.	56	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.6	1.5	2.1	6.0	9.2	6.1	9.7	8.8	0.7	1.4
C25	Pancreas	36	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.2	0.0	0.7	4.1	3.4	0.0	5.1	6.0	7.7	0.4	0.9
C30-C31	Nose, sinuses, etc.	3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1
C32	Larynx	4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
C33-C34	Trachea, Bronchus, Lung	59	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.2	1.4	2.2	1.5	4.0	6.9	6.1	12.1	11.0	0.7	1.4
C37-C38	Other Thoracic Organs	10	0.0	0.4	0.0	0.2	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.1
C40-C41	Bone	37	0.0	0.0	0.6	0.7	0.8	0.3	0.6	0.4	0.4	0.3	0.7	0.5	0.0	0.8	0.0	0.0	0.0	0.5	0.4
C43	Melanoma of Skin	7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.1	0.2
C44	Other Skin	113	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.4	2.1	0.8	3.7	3.6	6.0	9.9	11.2	25.4	26.4	1.4	2.6
C45	Mesothelioma	7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	1.0	0.0	1.5	1.0	0.0	0.0	0.1	0.2
C46	Kaposi sarcoma	5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.5	0.0	0.8	1.0	0.0	0.0	0.1	0.1
C47; C49	Connective, Soft Tissue	53	0.0	1.3	0.0	0.2	0.8	0.4	0.3	0.9	0.8	0.6	1.5	2.1	0.7	0.8	1.0	0.0	4.4	0.7	0.8
C50	Breast	676	0.0	0.0	0.0	0.0	0.1	1.3	3.2	10.4	18.1	27.5	44.4	41.7	37.5	42.0	34.5	33.9	25.3	8.4	13.9
C51	Vulva	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.3	0.8	0.0	2.2	0.1	0.1
C52	Vagina	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C53	Cervix Uteri	87	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.9	1.9	3.6	4.8	5.7	4.7	5.3	8.1	10.9	2.2	1.1	1.9
C54	Corpus Uteri	112	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	2.8	5.2	4.6	12.1	12.2	16.2	18.1	11.0	1.4	2.8
C55	Uterus Unspec.	9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.4	1.5	0.7	0.8	0.0	0.0	0.0	0.1	0.2
C56	Ovary	109	0.0	0.1	0.2	0.3	0.8	0.9	0.7	1.6	2.3	2.5	3.7	3.1	10.7	3.1	4.1	14.5	3.3	1.4	2.0
C57	Other Female Genital	5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.7	1.5	0.0	0.0	0.0	0.1	0.1
C58	Placenta	6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.3	0.4	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.1
C64	Kidney	62	0.0	0.8	0.2	0.0	0.1	0.1	0.1	0.5	1.2	1.7	1.8	2.6	5.4	7.6	3.0	1.2	2.2	0.8	1.3
C65	Renal pelvis	2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.1	0.0	0.1
C66	Ureter	1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Bladder	42	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.4	0.3	0.4	2.6	4.0	5.3	5.1	2.4	12.1	0.5	1.0
C68	Other urinary organs	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	15	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.8	1.0	0.0	1.1	0.2	0.2
C70-C72	Brain, Nervous System	81	0.0	0.7	1.1	0.9	0.8	0.1	0.3	0.4	0.8	1.4	1.8	1.5	4.0	4.6	4.1	4.8	3.3	1.0	1.3
C73	Thyroid	343	1.0	0.0	0.1	0.4	2.3	4.6	4.2	8.9	9.5	11.3	9.2	14.4	10.7	11.5	7.1	13.3	13.2	4.3	5.7
C74	Adrenal gland	12	0.0	0.4	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.1	0.2
C75	Other Endocrine	1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C81	Hodgkin Disease	104	0.0	0.0	0.6	1.1	2.4	2.7	1.2	1.1	1.0	0.3	1.8	0.5	3.4	3.1	2.0	1.2	5.5	1.3	1.4
C82-C85; C96	Non Hodgkin lymphoma	218	0.0	1.1	0.2	1.0	1.0	1.3	1.2	2.0	1.4	3.3	5.9	8.2	6.0	19.1	26.4	24.2	27.5	2.7	4.5
C88	Immunoproliferative dis.	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C90	Multiple Myeloma	12	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.7	3.1	2.0	2.4	1.1	0.1	0.3
C91	Lymphoid Leukaemia	84	0.0	3.0	1.8	0.4	0.8	0.4	0.6	0.2	0.4	0.6	0.7	1.0	1.3	1.5	1.0	1.2	1.1	1.0	1.1
C92-C94	Myeloid Leukaemia	95	0.0	0.4	0.4	0.4	0.7	1.3	1.3	2.0	1.0	3.3	1.1	2.6	2.7	3.1	5.1	4.8	4.4	1.2	1.5
C95	Leukaemia unspec.	5	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
Other	Other & unspecified	155	0.0	0.3	0.0	0.1	0.5	0.3	0.3	0.5	0.6	3.3	3.7	6.2	12.1	18.3	19.3	19.3	27.5	1.9	3.7
All	All Ages Total	3253	1.0	9.9	5.6	6.5	12.2	15.8	16.3	35.9	49.3	79.9	117.1	144.8	188.2	244.7	250.4	277.8	295.9	40.3	66.3
Not C44	All sites but C44	3140	1.0	9.8	5.6	6.5	12.2	15.7	16.2	35.5	47.2	79.1	113.4	141.2	182.2	234.8	239.2	252.4	269.5	38.9	63.7

Table 5.3.1 Age Distribution of Cancer Cases among non-Saudi Males, 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	2	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	11.4	0	0.2
C01-C02	Tongue	14	0	0	0	0	0	0.3	0	0	0.6	0.4	0.6	1.1	2.4	2.6	0	0	0	0.3	0.4
C03-C06	Mouth	8	0	0.5	0	0	0	0	0	0	0.3	0	0	0	2.4	2.6	6.1	0	11.4	0.2	0.7
C07-C08	Salivary Glands	6	0	0	0	0	0	0	0.2	0	0.2	0.4	0	0	1.2	2.6	0	0	0	0.1	0.2
C9	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0	0.1
C10	Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	25	0	0	0	0	1.4	0.3	0	0.1	0.3	0.6	3.3	0.5	1.2	7.8	0	0	0	0.6	0.8
C12-C13	Hypopharynx	5	0	0	0	0	0	0	0	0.1	0	0.2	0.6	0	1.2	0	0	0	0	0.1	0.1
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	14	0	0	0	0	0	0	0	0.6	0	0.2	0.9	0	2.4	5.2	0	20.8	0	0.3	0.8
C16	Stomach	63	0	0	0	0	0	0.3	0	1.2	1.2	1.2	3.6	4.8	6	10.4	6.1	83.3	11.4	1.5	3.4
C17	Small intestine	4	0	0	0	0	0	0	0	0.1	0	0.4	0	0	1.2	0	0	0	0	0.1	0.1
C18	Colon	70	0	0	0	0	0	0.3	0.5	0.6	1.7	1.8	4.8	4.8	7.2	7.8	18.4	10.4	45.6	1.7	3.1
C19-C20	Rectum	58	0	0	0	0	0	0.7	0.3	0.7	0.5	1.8	3	3.7	9.7	12.9	36.8	10.4	0	1.4	2.8
C21	Anus	10	0	0	0	0	0	0	0	0.1	0.2	0	0.6	0.5	2.4	0	6.1	0	22.8	0.2	0.8
C22	Liver	45	0	0	0	0	0	0	0	0	0.8	1.4	2.4	2.7	0	18.1	43	52.1	11.4	1.1	3.7
C23-C24	Gall bladder ect.	6	0	0	0	0	0	0	0	0	0	0.2	0.6	0.5	0	0	6.1	0	11.4	0.1	0.5
C25	Pancreas	11	0	0	0	0	0	0	0	0	0	0.2	0.6	0.5	2.4	2.6	6.1	10.4	22.8	0.3	1.1
C30-C31	Nose, sinuses, etc.	5	0	0	0	0	0	0	0	0	0	0.2	0.9	0	0	0	0	0	11.4	0.1	0.3
C32	Larynx	30	0	0	0	0	0	0.3	0.2	0	0.3	0.6	1.2	1.6	10.9	10.4	0	10.4	22.8	0.7	1.8
C33-C34	Trachea, Bronchus, Lung	65	0	0	0	0	0	0	0	0.1	0.8	1	2.7	6.4	14.5	31.1	6.1	31.2	57	1.6	4.4
C37-C38	Other Thoracic Organs	11	0	0	0	0	0	0	0.2	0.4	0	1	0.3	0	0	2.6	0	0	0	0.3	0.2
C40-C41	Bone	16	0	0	1	0	4.1	1	0.2	0.1	0	0	0.3	0	0	2.6	0	0	11.4	0.4	0.9
C43	Melanoma of Skin	4	0	0	0	0	0	0	0.2	0	0	0	0	1.6	0	0	0	0	0	0.1	0.1
C44	Other Skin	81	0	0	0	0	0	0.3	0	0.3	0.6	1.4	5.1	6.4	20.5	18.1	49.1	31.2	34.2	1.9	5.1
C45	Mesothelioma	5	0	0	0	0	0	0	0	0.1	0	0	0	0	1.2	2.6	6.1	0	11.4	0.1	0.6
C46	Kaposi sarcoma	4	0	0	0	0	0	0	0	0	0	0.2	0.3	0.5	0	0	0	10.4	0	0.1	0.3
C47; C49	Connective, Soft Tissue	25	0	1.4	0.5	0.6	0.7	0	0	0.4	0.2	0.2	3.3	0.5	1.2	0	0	0	11.4	0.6	0.9
C50	Breast	8	0	0	0	0	0	0.3	0	0	0	0.4	0.3	1.1	0	2.6	6.1	0	0	0.2	0.4
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C61	Prostate	47	0	0	0	0	0	0	0	0	0	0	0.3	3.2	14.5	28.5	55.3	41.6	45.6	1.1	5.3
C62	Testis	21	0	0	0	0	0.7	0.7	0.5	1	0.6	0.6	0	0	1.2	0	0	0	0	0.5	0.3
C63	Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C64	Kidney	27	0	0	0	0	0	0	0.2	0	0.3	1	2.1	2.1	4.8	5.2	6.1	0	11.4	0.6	1.1
C65	Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0	0.1
C67	Bladder	61	0	0	0.5	0	0	0.3	0	0.5	1.2	2.1	2.1	10.1	6	20.7	24.6	31.2	45.6	1.5	4.2
C68	Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	10	0	1.4	0	0	0	0	0.2	0.1	0.5	0.2	0	0	0	2.6	0	0	0	0.2	0.3
C70-C72	Brain, Nervous System	40	0	0	2.5	1.2	0.7	0.3	0.2	0.9	0.2	1.2	2.4	1.6	2.4	2.6	6.1	20.8	0	1	1.6
C73	Thyroid	25	0	0	0.5	0	1.4	0.7	0.2	0.3	0.5	1.4	0.6	1.6	1.2	0	6.1	0	0	0.6	0.7
C74	Adrenal gland	4	0	1.4	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0.1	0.2
C75	Other Endocrine	1	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	31	0	0.9	2.5	0.6	0	0.3	0.5	0.7	0.6	0.8	0.6	1.1	2.4	0	0	0	0	0.7	0.8
C82-C85; C96	Non Hodgkin lymphoma	78	0	1.8	1	0.6	2.7	1.4	0.5	0.9	1.2	2.2	1.2	4.8	15.7	7.8	30.7	0	11.4	1.9	3.4
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.1	0	0	0	0.2
C90	Multiple Myeloma	8	0	0	0	0	0	0	0	0	0	0.2	0.3	0.5	1.2	5.2	12.3	0	0	0.2	0.7
C91	Lymphoid Leukaemia	36	0	3.7	1.5	2.3	4.1	0.3	0.5	0.1	0.3	0.2	0.3	1.6	2.4	2.6	0	0	0	0.9	1.6
C92-C94	Myeloid Leukaemia	35	0	0	0.5	1.2	0	1.7	0.3	1.3	0.5	0.2	1.5	1.6	1.2	5.2	6.1	0	0	0.8	1
C95	Leukaemia unspec.	5	0	0	0	0.6	0	0.3	0	0	0	0	0.9	0	0	0	0	0	0	0.1	0.1
Other	Other & unspecified	46	0	0	0	0.6	0.7	0.3	0	0.3	0.8	1	1.5	4.8	6	18.1	12.3	10.4	22.8	1.1	2.6
All	All Ages Total	1074	0.0	11.1	10.5	7.7	16.5	10.1	4.9	10.6	13.9	24.2	49.5	70.2	147.0	246.3	361.8	374.6	444.6	25.4	58.0
Not C44	All sites but C44	993	0.0	11.1	10.5	7.7	16.5	9.8	4.9	10.3	13.3	22.8	44.4	63.8	126.5	228.2	312.7	343.4	410.4	23.5	52.9

Table 5.3.2 Age Distribution of Cancer Cases among non-Saudi Females, 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	2	0	0	0	0	0	0	0	0	0	0	0	2.4	0	0	0	0	14.2	0.1	0.4
C01-C02	Tongue	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0.2
C03-C06	Mouth	7	0	0	0	0	0	0	0	0	0	0	2.8	2.4	4.7	0	13.1	0	14.2	0.4	1.2
C07-C08	Salivary Glands	1	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	0	0	0	0.1	0.1
C9	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	4.7	0	0	0	0	0.1	0.2
C11	Nasopharynx	8	0	0	0	0	0	1.3	0.4	0	1.1	1.7	0	0	0	0	0	0	0	0.4	0.3
C12-C13	Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	0	0	0	0.1	0.1
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	8	0	0	0	0	0	0	0	0	0.5	0.8	0	2.4	0	6.8	0	0	56.7	0.4	1.6
C16	Stomach	9	0	0	0	0	0	0	0	0	0	1.7	1.4	7.1	4.7	0	26.1	0	0	0.5	1.5
C17	Small intestine	3	0	0	0	0	0	0	0	0.4	0	0	1.4	2.4	0	0	0	0	0	0.2	0.2
C18	Colon	29	0	0	0	0	0	0.6	0.9	0.4	0.5	2.5	1.4	14.1	47.3	6.8	26.1	0	14.2	1.6	4.3
C19-C20	Rectum	21	0	0	0	0	0	0	0.9	0.8	1.1	3.4	7.0	7.1	9.5	0	0	16.1	0	1.1	1.9
C21	Anus	5	0	0	0	0	0	0	0	0	0	0	4.2	2.4	0	0	13.1	0	0	0.3	0.8
C22	Liver	6	0	0	0	0	0	0	0	0.4	0	0	1.4	0	9.5	6.8	13.1	0	0	0.3	1.2
C23-C24	Gall bladder ect.	6	0	0	0	0	0	0	0	0	0	0.8	0	0	4.7	13.7	13.1	0	14.2	0.3	1.5
C25	Pancreas	10	0	0	0	0	0	0	0	0	0	0.8	1.4	2.4	14.2	0	39.2	0	14.2	0.5	2.3
C30-C31	Nose, sinuses, etc.	1	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0	0	0	0	0.1	0
C32	Larynx	4	0	0	0	0	0	0	0	0	1.1	0	0	0	4.7	6.8	0	0	0	0.2	0.5
C33-C34	Trachea, Bronchus, Lung	15	0	0	0	0	0	0	0.4	0	0	0	0.8	1.4	2.4	0	0	0	0	0.1	0.1
C37-C38	Other Thoracic Organs	7	0	0	0.5	0	1.4	0	0	0.4	0.5	0	1.4	2.4	0	0	0	0	0	0.4	0.4
C40-C41	Bone	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C43	Melanoma of Skin	47	0	0.5	0	0	0	0.6	1.3	2.3	1.6	5.0	7.0	16.5	14.2	13.7	39.2	80.3	28.3	2.6	6.4
C44	Other Skin	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.2
C45	Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	4.7	0	0	0	0	0.1	0.2
C46	Kaposi sarcoma	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.2
C47; C49	Connective, Soft Tissue	246	0	0.5	0	0	2.2	1.9	0.9	0.8	0.5	1.7	1.4	0	0	6.8	0	0	14.2	0.9	1.3
C50	Breast	2	0	0	0	0	0	1.9	3.0	9.8	21.6	29.4	61.9	96.5	75.7	88.9	143.6	32.1	113.3	13.4	26.4
C51	Vagina	1	0	0	0	0	0	0	0	0	0.5	0	0	0	4.7	0	0	0	0	0.1	0.2
C52	Cervix Uteri	36	0	0	0	0	0	0.6	0.9	0.8	2.7	10.9	5.6	7.1	18.9	0	26.1	0	0	0.1	0.1
C53	Corpus Uteri	24	0	0	0	0	0	0	0.4	0.4	1.1	2.5	1.4	9.4	28.4	20.5	13.1	32.1	0	2	3.2
C54	Uterus Unspec.	5	0	0	0	0	0	0	0	0	0	0.8	2.8	2.4	0	0	13.1	0	0	1.3	3.8
C55	Ovary	36	0	0.9	0	0	1.4	1.3	0.4	1.5	2.2	2.5	1.4	21.2	9.5	13.7	13.1	32.1	14.2	0.3	0.7
C56	Other Female Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	4.1
C57	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C58	Kidney	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C64	Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	27.4	0	0	0	0.3	1.2
C65	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Bladder	11	0	0	0	0	0	0	0	0.4	2.2	0	0	7.1	0	6.8	13.1	16.1	0	0.6	1.5
C67	Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C68	Eye	5	0	1.9	0	0	0	0	0	0	0	0	0	0	4.7	0	0	0	0	0	0
C69	Brain, Nervous System	15	0	0.9	0.5	0.6	0	0.6	0	0.4	0	2.5	1.4	4.7	9.5	0	13.1	0	0	0.3	0.4
C70-C72	Thyroid	58	0	0	0	0.6	1.4	0	4.3	3.4	7.0	8.4	5.6	4.7	9.5	20.5	13.1	0	14.2	0.8	1.5
C73	Adrenal gland	4	0	1.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.2	4.1
C74	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0.2
C75	Hodgkin Disease	16	0	0	0	0.6	3.6	0.6	1.3	0.4	0	0	1.4	0	9.5	6.8	0	16.1	0	0	1.6
C81	Non Hodgkin Lymphoma	33	0	0.5	1.8	2.2	0	0.6	0	0.8	1.1	0.8	4.2	16.5	9.5	13.7	13.1	48.2	14.2	1.8	4.3
C82-C85; C96	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C88	Multiple Myeloma	5	0	0	0	0	0	0	0	0	0.5	0	1.4	0	9.5	6.8	0	0	0	0.3	0.8
C90	Lymphoid Leukaemia	23	0	5.7	2.1	0.6	1.4	0	0	0	0	1.7	0	0	4.7	0	0	0	14.2	1.3	1.6
C91	Myeloid Leukaemia	18	0	0.5	0	1.2	0	0.6	1.3	0.8	1.6	1.7	0	4.7	0	0	0	32.1	0	1	1.4
C92-C94	Leukaemia unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C95	Other & unspecified	27	0	0.5	0	0	0	0	0.9	0.8	1.6	3.4	4.2	4.7	23.7	0	26.1	32.1	14.2	1.5	3.6
Other	All Ages Total	792	0	13.8	4.1	5.4	13.6	12.4	17.3	25.4	50.0	87.0	127.7	247.7	364.4	273.3	522.7	369.4	397.0	43.6	92.2
All	Not C44	745	0	13.8	3.6	5.4	13.6	11.8	16.0	23.1	48.4	82.0	120.7	231.2	350.2	259.6	483.5	289.1	368.7	41.0	85.8

Table 5.3.3 Incidence Rates for Cancer Cases among non- Saudi Males by Age Group (per 100,000), 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	2	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	11.4	0	0.2
C01-C02	Tongue	14	0	0	0	0	0	0.3	0	0	0.6	0.4	0.6	1.1	2.4	2.6	0	0	0	0.3	0.4
C03-C06	Mouth	8	0	0.5	0	0	0	0	0	0	0.3	0	0	0	2.4	2.6	6.1	0	11.4	0.2	0.7
C07-C08	Salivary Glands	6	0	0	0	0	0	0	0.2	0	0.2	0.4	0	0	1.2	2.6	0	0	0	0.1	0.2
C9	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0	0.1
C10	Other oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	25	0	0	0	0	1.4	0.3	0	0.1	0.3	0.6	3.3	0.5	1.2	7.8	0	0	0	0.6	0.8
C12-C13	Hypopharynx	5	0	0	0	0	0	0	0	0.1	0	0.2	0.6	0	1.2	0	0	0	0	0.1	0.1
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	14	0	0	0	0	0	0	0	0.6	0	0.2	0.9	0	2.4	5.2	0	20.8	0	0.3	0.8
C16	Stomach	63	0	0	0	0	0	0.3	0	1.2	1.2	1.2	3.6	4.8	6	10.4	6.1	83.3	11.4	1.5	3.4
C17	Small intestine	4	0	0	0	0	0	0	0	0.1	0	0.4	0	0	1.2	0	0	0	0	0.1	0.1
C18	Colon	70	0	0	0	0	0	0.3	0.5	0.6	1.7	1.8	4.8	4.8	7.2	7.8	18.4	10.4	45.6	1.7	3.1
C19-C20	Rectum	58	0	0	0	0	0	0.7	0.3	0.7	0.5	1.8	3	3.7	9.7	12.9	36.8	10.4	0	1.4	2.8
C21	Anus	10	0	0	0	0	0	0	0	0.1	0.2	0	0.6	0.5	2.4	0	6.1	0	22.8	0.2	0.8
C22	Liver	45	0	0	0	0	0	0	0	0	0.8	1.4	2.4	2.7	0	18.1	43	52.1	11.4	1.1	3.7
C23-C24	Gall bladder ect.	6	0	0	0	0	0	0	0	0	0	0.2	0.6	0.5	0	0	6.1	0	11.4	0.1	0.5
C25	Pancreas	11	0	0	0	0	0	0	0	0	0	0.2	0.6	0.5	2.4	2.6	6.1	10.4	22.8	0.3	1.1
C30-C31	Nose, sinuses, etc.	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11.4	0.1	0.3
C32	Larynx	30	0	0	0	0	0	0.3	0.2	0	0.3	0.6	1.2	1.6	10.9	10.4	0	10.4	22.8	0.7	1.8
C33-C34	Trachea, Bronchus, Lung	65	0	0	0	0	0	0	0	0.1	0.8	1	2.7	6.4	14.5	31.1	6.1	31.2	57	1.6	4.4
C37-C38	Other Thoracic Organs	11	0	0	0	0	0	0	0.2	0.4	0	1	0.3	0	0	2.6	0	0	0	0.3	0.2
C40-C41	Bone	16	0	0	1	0	4.1	1	0.2	0.1	0	0	0.3	0	0	2.6	0	0	11.4	0.4	0.9
C43	Melanoma of Skin	4	0	0	0	0	0	0	0	0	0	0	0	1.6	0	0	0	0	0	0.1	0.1
C44	Other Skin	81	0	0	0	0	0	0.3	0	0.3	0.6	1.4	5.1	6.4	20.5	18.1	49.1	31.2	34.2	1.9	5.1
C45	Mesothelioma	5	0	0	0	0	0	0	0	0.1	0	0	0	0	1.2	2.6	6.1	0	11.4	0.1	0.6
C46	Kaposi sarcoma	4	0	0	0	0	0	0	0	0	0	0.2	0.3	0.5	0	0	0	10.4	0	0.1	0.3
C47; C49	Connective, Soft Tissue	25	0	1.4	0.5	0.6	0.7	0	0	0.4	0.2	0.2	3.3	0.5	1.2	0	0	0	11.4	0.6	0.9
C50	Breast	8	0	0	0	0	0	0.3	0	0	0	0.4	0.3	1.1	0	2.6	6.1	0	0	0.2	0.4
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C61	Prostate	47	0	0	0	0	0	0	0	0	0	0	0	3.2	14.5	28.5	55.3	41.6	45.6	1.1	5.3
C62	Testis	21	0	0	0	0	0.7	0.7	0.5	1	0.6	0.6	0	0	1.2	0	0	0	0	0.5	0.3
C63	Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C64	Kidney	27	0	0	0	0	0	0	0.2	0	0.3	1	2.1	2.1	4.8	5.2	6.1	0	11.4	0.6	1.1
C65	Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	0	0	0.1
C67	Bladder	61	0	0	0.5	0	0	0.3	0	0	0.5	1.2	2.1	10.1	6	20.7	24.6	31.2	45.6	1.5	4.2
C68	Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	10	0	1.4	0	0	0	0	0.2	0.1	0.5	0.2	0	0	0	2.6	0	0	0	0.2	0.3
C70-C72	Brain, Nervous System	40	0	0	2.5	1.2	0.7	0.3	0.2	0.9	0.2	1.2	2.4	1.6	2.4	2.6	6.1	20.8	0	1	1.6
C73	Thyroid	25	0	0	0.5	0	1.4	0.7	0.2	0.3	0.5	1.4	0.6	1.6	1.2	0	6.1	0	0	0.6	0.7
C74	Adrenal gland	4	0	1.4	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0.1	0.2
C75	Other Endocrine	1	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	31	0	0.9	2.5	0.6	0	0.3	0.5	0.7	0.6	0.8	0.6	1.1	2.4	0	0	0	0	0.7	0.8
C82-C85; C96	Non Hodgkin lymphoma	78	0	1.8	1	0.6	2.7	1.4	0.5	0.9	1.2	2.2	1.2	4.8	15.7	7.8	30.7	0	11.4	1.9	3.4
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.1	0	0	0	0.2
C90	Multiple Myeloma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C91	Lymphoid Leukaemia	36	0	3.7	1.5	2.3	4.1	0.3	0.5	0.1	0.3	0.2	0.3	1.6	2.4	2.6	0	0	0	0.9	1.6
C92-C94	Myeloid Leukaemia	35	0	0	0.5	1.2	0	1.7	0.3	1.3	0.5	0.2	1.5	1.6	1.2	5.2	6.1	0	0	0.8	1
C95	Leukaemia unspec.	5	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1
Other	Other & unspecified	46	0	0	0	0	0.6	0.7	0.3	0	0.3	0.8	1	1.5	4.8	6	18.1	12.3	10.4	22.8	1.1
All	All sites	1074	0.0	11.1	10.5	7.7	16.5	10.1	4.9	10.6	13.9	24.2	49.5	70.2	147.0	246.3	361.8	374.6	444.6	25.4	58.0
All but C44	All sites but C44	993	0.0	11.1	10.5	7.7	16.5	9.8	4.9	10.3	13.3	22.8	44.4	63.8	126.5	228.2	312.7	343.4	410.4	23.5	52.9

Table 5.3.4 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100,000), 2003

ICD10	SITE	Tot	UNK	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	14.2	0.1	0.4
C01-C02	Tongue	3	0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.8	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2
C03-C06	Mouth	7	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	2.8	2.4	4.7	0.0	13.1	0.0	14.2	0.4	1.2
C07-C08	Salivary Glands	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
C9	Tonsil	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0
C10	Other oropharynx	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.1	0.2
C11	Nasopharynx	8	0	0.0	0.0	0.0	0.0	1.3	0.4	0.4	1.1	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3
C12-C13	Hypopharynx	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
C14	Pharynx unspec.	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0
C15	Oesophagus	8	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.8	0.0	2.4	0.0	6.8	0.0	0.0	56.7	0.4	1.6
C16	Stomach	9	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	1.4	7.1	4.7	0.0	26.1	0.0	0.0	0.5	1.5
C17	Small intestine	3	0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.2	0.2
C18	Colon	29	0	0.0	0.0	0.0	0.0	0.6	0.9	0.4	0.5	2.5	1.4	14.1	47.3	6.8	26.1	0.0	14.2	1.6	4.3
C19-C20	Rectum	21	0	0.0	0.0	0.0	0.0	0.0	0.9	0.8	1.1	3.4	7.0	7.1	9.5	0.0	16.1	0.0	1.1	0.0	1.9
C21	Anus	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	2.4	0.0	0.0	13.1	0.0	0.0	0.3	0.8
C22	Liver	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.4	0.0	9.5	6.8	13.1	0.0	0.0	0.3	1.2
C23-C24	Gall bladder ect.	6	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	4.7	13.7	13.1	0.0	14.2	0.3	1.5
C25	Pancreas	10	0	0.0	0.0	0.0	0.0	0.6	1.3	2.3	1.6	5.0	7.0	16.5	14.2	6.8	39.2	80.3	28.3	2.6	6.4
C30-C31	Nose, sinuses, etc.	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0
C32	Larynx	4	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	4.7	6.8	0.0	0.0	0.0	0.2	0.5
C33-C34	Trachea, Bronchus, Lung	15	0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.8	1.4	2.4	9.5	0.0	52.2	32.1	42.5	0.8	3.7
C37-C38	Other Thoracic Organs	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.4	2.4	0.0	0.0	0.0	14.2	0.5	2.3
C40-C41	Bone	7	0	0.0	0.5	0.0	1.4	0.0	0.0	0.4	0.5	0.0	1.4	2.4	0.0	0.0	0.0	0.0	0.0	0.1	0
C43	Melanoma of Skin	6	0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	14.2	6.8	0.0	0.0	0.0	0.4	0.4
C44	Other Skin	47	0	0.0	0.5	0.0	0.0	0.6	1.3	2.3	1.6	5.0	7.0	16.5	14.2	6.8	39.2	80.3	28.3	2.6	6.4
C45	Mesothelioma	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.1	0.2
C46	Kaposi sarcoma	1	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.1	0.2
C47; C49	Connective, Soft Tissue	17	0	0.5	0.0	0.0	2.2	1.9	0.9	0.8	0.5	1.7	1.4	0.0	4.7	6.8	0.0	0.0	14.2	0.9	1.3
C50	Breast	246	0	0.0	0.0	0.0	0.0	1.9	3.0	9.8	21.6	29.4	61.9	96.5	75.7	88.9	143.6	32.1	113.3	13.4	26.4
C51	Vulva	2	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.1	0.2
C52	Vagina	1	0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1
C53	Cervix Uteri	36	0	0.0	0.0	0.0	0.0	0.6	0.9	0.8	2.7	10.9	5.6	7.1	18.9	0.0	26.1	0.0	0.0	2	3.2
C54	Corpus Uteri	24	0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	1.1	2.5	1.4	9.4	28.4	20.5	13.1	32.1	0.0	1.3	3.8
C55	Uterus Unspec.	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	2.8	2.4	0.0	0.0	13.1	0.0	0.0	0.3	0.7
C56	Ovary	36	0	0.9	0.0	0.0	1.4	1.3	0.4	1.5	2.2	2.5	1.4	21.2	9.5	13.7	13.1	32.1	14.2	2	4.1
C57	Other Female Genital	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0
C58	Placenta	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0
C64	Kidney	6	0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.8	0.0	0.0	0.0	27.4	0.0	0.0	0.0	0.3	1.2
C65	Renal pelvis	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C66	Ureter	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C67	Bladder	11	0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.2	0.0	0.0	7.1	0.0	6.8	13.1	16.1	0.0	0.6	1.5
C68	Other urinary organs	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C69	Eye	5	0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.3	0.4
C70-C72	Brain, Nervous System	15	0	0.9	0.5	0.6	0.0	0.6	0.0	0.4	0.0	2.5	1.4	4.7	9.5	0.0	13.1	0.0	0.0	0.8	1.5
C73	Thyroid	58	0	0.0	0.0	0.6	1.4	0.0	4.3	3.4	7.0	8.4	5.6	4.7	9.5	20.5	13.1	0.0	14.2	3.2	4.1
C74	Adrenal gland	4	0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2
C75	Other Endocrine	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0
C81	Hodgkin Disease	16	0	0.0	0.0	0.6	3.6	0.6	1.3	0.4	0.0	0.0	1.4	0.0	9.5	6.8	0.0	16.1	0.0	0.9	1.6
C82-C85; C96	Non Hodgkin lymphoma	33	0	0.5	0.5	1.8	2.2	0.6	0.0	0.8	1.1	0.8	4.2	16.5	9.5	13.7	13.1	48.2	14.2	1.8	4.3
C88	Immunoproliferative dis.	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C90	Multiple Myeloma	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.4	0.0	9.5	6.8	0.0	0.0	0.0	0.3	0.8
C91	Lymphoid Leukaemia	23	0	5.7	2.1	0.6	1.4	0.0	0.0	0.0	0.0	1.7	0.0	0.0	4.7	0.0	0.0	0.0	14.2	1.3	1.6
C92-C94	Myeloid Leukaemia	18	0	0.5	0.0	1.2	0.0	0.6	1.3	0.8	1.6	1.7	0.0	4.7	0.0	0.0	0.0	32.1	0.0	1	1.4
C95	Leukaemia unspec.	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0
Other	Other & unspecified	27	0	0.5	0.0	0.0	0.0	0.0	0.9	0.8	1.6	3.4	4.2	4.7	23.7	0.0	26.1	32.1	14.2	1.5	3.6
All	All sites	792	0	13.8	4.1	5.4	13.6	12.4	17.3	25.4	50.0	87.0	127.7	247.7	364.4	273.3	522.7	369.4	397.0	43.6	92.2
All but C44	All sites but C44	745	0	13.8	3.6	5.4	13.6	11.8	16.0	23.1	48.4	82.0	120.7	231.2	350.2	259.6	483.5	289.1	368.7	41.0	85.8

PART VI

APPENDICES

APPENDIX: A Reporting Health care Facilities

Asir Region

Abha Private Hospital	Mahael General Hospital
Armed Forces Hospital South	Majaridah General Hospital
Ahad Rafidah General Hospital	Maternity & Children's Hospital
Ahli Hospital	Namad General Hospital
Asir Central Hospital	King Abdullah Bin Abdul Aziz
Asir Hospital NOS	Rijal Al Maa
Balasmr General Hospital	Sabt Al Alaya
Bisha General Hospital	Sarat Obeidah General Hospital
Dhahran Al Janoob	Saudi German Hospital (Abha)
Khamys Mishayt Civil Hospital	Thaleeth General Hospital
King Fahd Armed Forces Hospital	
King Faisal Military Hospital	

Baha Region

Baha Hospital NOS	King Abdullah Bin Abdul Aziz
Baljurashi General Hospital	

Eastern Province

Al Ahsa Hospital (Hofuf)	King Fahd Hospital in the Eastern Province
Al Mana General Hospital (Dammam)	King Fahd Military
Al Mana General Hospital (Khobar)	King Khalid General Hospital
Al Mana General Hospital (Hofuf)	King Khaled Military Clinic
Al Mana General Hospital (Jubail)	Maternity & Children's Hospital
Arabian Oil Company Hospital	Maternity & Children's Hospital
Armed Forces Hospital (Hafr Baten)	Mousa Hospital (Hofuf)
Astoon Hospital (Thomairy) (Dammam)	Mouwasat Hospital
Chest Disease Hospital	Mouwasat Dispensary
Dammam Central Hospital	Obeid Hospital (Hofuf)
Dhahran Medical Center	Prince Saud Bin Jalawi Hospital
Dossary Hospital	Qatif Central Hospital
Dr Fakhry & Mouhawis	Rasheed Hospital
Fanateer Hospital	Rowdha Dispensary
Harbeesh Hospital (Hofuf)	Saad Specialist Medical Center
Jubail Hospital	Safwa Hospital
Jufer Hospital	Salama Hospital
Khafji Operation Hospital	Tadawy General Hospital
Khafji General Hospital	Taheeli
King Abdul Aziz Air Base Hospital	Uyun Hospital
King Abdul Aziz Navy Hospital	Yousif Hospital
King Abdul Aziz National hospital	Zamil Hospital
King Fahd Hospital (Hofuf)	

Hail Region

Hail General Hospital	Rashid Hospital
King Khaled General Hospital, Hail	Baqa Hospital

Jazan Region

King Fahd General Hospital	Samtah General Hospital
Jazan General Hospital	

APPENDIX: A (continued...)

Jouf Region

Dawamat Jandal Jouf Hospital, NOS Prince Abdul Rahman Sudairi Hospital Quarayat General Hospital	Skaka General Hospital Tabarjal General Hospital
---	---

Madinah Region

Al Dar Hospital Ansar Hospital Badr General Hospital Dr. Hamed Al Ahmadi Hospital Hanakyah Hospital Khaybar General Hospital King Fahd Hospital Madinah National Hospital Mahad Hospital Maternity & Children's Hospital Meeqat Hospital	Mouwasat Hospital Ohoud Hospital Psychaitric Hospital Taiba Private Hospital Tariq Bin Laden Hospital Ula General (Prince Abdullah Bin Abdul Aziz) Yanboa Al Bahr Hospital Yanboa General Hospital Zahra Private Hospital
--	---

Makkah Region

Abuzinada Hospital Ajiyad General Hospital Al Abraj Laboratory Alawi Tunsi & Bros Hospital Amen Hospital Ansar Hospital Bakhsh Hospital Bugshan General Hospital Children & Maternity Hospital Dr. Erfan & Bagedo Hospital Dr. Ghassan Pharaon Dr. Solaiman Fakeeh Hospital El Maghraby Eye Hospital Eye Hospital (JD) Hada Military Hospital Hai Al Jamea Hamra Hassan National Hospital Hera General Hospital Ibn Sina Jedaani Hospital Jeddah Regional Laboratory Khurama Hospital King Abdul Aziz Hospital (Taif) King Abdul Aziz Al Zaher King Abdul Aziz Hospital & Oncology Center King Abdul Aziz Medical City	King Abdul Aziz University Hospital King Fahad Armed Forces Hospital King Fahad General Hospital King Faisal (Taif) King Faisal Al Sheshah Hospital King Faisal Specialist Hospital & Research Centre M S Bashrahil Makkah Hospital NOS Maternity & Children's Hospital Mustaqbal (Dhagastani) Nahda National New Jeddah Clinic Noor Specialist Hospital Qunfudah General Hospital Rabegh General Hospital Ranyah Hospital Royal Commission Salamah Hospital Saudi German (JD) Saudia Airlines Med Services Sheffaa Hospital Taif Chest Hospital Thagher Hospital Umm Al Qura Poly Clinic United Doctors Hospital Yanboa General Hospital
--	--

APPENDIX: A (continued...)

Najran Region

Armed Forces Hospital Najran	Najran Hosp NOS
Armed Forces Hospital Sharoura	Sharourah General Hospital
King Khaled General Hospital	
Najran General Hospital	

Northern Region

Arar Central Hospital	Turayf General
Rafha General Hospital	

Qassim Region

Bukairiya General Hospital	Midhnab General Hospital
Buraidah Central Hospital	Onaizah General Hospital
King Fahd Specialist Hospital	Qassim Hospital NOS (not otherwise specified)
King Saud Hospital (Onaizah)	Rass General Hospital
Maternity and Children Hospital	

Riyadh Region

Riyadh-Al Kharj Armed forces Hospital	King Khaled General Hospital
Affif General	King Khaled General (Majma'a)
Aflaj General Hospital	King Khaled University Hospital
Al Amal Clinic	Mamlaka (Kingdom) Hospital
Al Borg Laboratory	Mobarak Hospital
Armed Forces Wadi Dawasir	Mouwasat Riyadh
Artwiyah Clinic	Nukhba Medical Center
Chest Diseases Center	Obeid Hospital
College of Dentistry	Olaya Medical Center
Consulting Clinic	Prince Salman Bin Abdul Aziz Hospital
Dallah Hospital	Quwayiyah Hospital
Dawadmi General Hospital	Riyadh Care Hospital (Social Insurance Hospital)
Dr Abdul Rahman Al Mishari Hospital	Riyadh Medical Complex
Dr. Al Moagel's Polyclinic	Saati Medical Center
Dr Al Mofarreh Polyclinic	Saudi German Hospital (Riyadh)
Dr. Fahd Al Shedoukhy	Security Forces
Dr Suliman Al Habib Medical Center	Shaqra Hospital
Eman General Hospital	Shifa Health Center
Faleh International hospital	Specialized Medical Center
Green Crescent Hospital	Sulail
Hammadi Hospital	Taawin Polyclinic
Hotta Bani Tammim Hospital	Taif Medical Center
Howtat Sudair	Usrah Hospital
Huraymila General Hospital	Wadi Al Dawasser
Kharj Hospital	Watani (Riyadh National hospital)
King Abdul Aziz Medical City	Yamamah Hospital
King Abdul Aziz University Hospital	Zulfi general Hospital
King Fahad Medical City	
King Faisal Specialist Hospital & Research Centre	
King Khaled Eye Specialist Hospital	

APPENDIX: A (continued....)

Tabuk Region

Dhuba Hospital	Prince Fahad Bin Sultan Hospital
Haql General Hospital	Tabuk Civil Hospital
King Fahad Hospital	Umm Lujj General Hospital
King Khalid General Hospital	
North West Armed Forces Hospital	

International Hospitals in the Following Countries

Bahrain	Qatar
Egypt	Singapore
Germany	Spain
India	Sudan
Jordan	Syrian Arab Republic
Kuwait	United Arab Emirates
Lebanon	United States of America
Oman	Yemen
Philippines	

APPENDIX: B NCR Board Member Contact Information

NCR Main Office MBC 64 PO Box 3354, Riyadh 11211 Saudi Arabia Tel: 01-442-3929 Fax: 01-442-3941 Website: www.kfshrc.edu.sa/NCR/ Email: bazarbashi@kfshrc.edu.sa haleid@kfshrc.edu.sa	Chairman: Dep. Chairman: Acting Admin. Director: Registrar: Registrar: Epidemiologist: Data Manager:	Shouki Bazarbashi, MD Nasser Al Hamdan, MD Haya Al Eid, BDS, DFE, CTR Mohamed Hayder, CTR Asif Mehmood, CTR Haya Al Eid, BDS, DFE, CTR Suad O. Arteh, MA
Armed Forces Hospitals Riyadh Military Hospital PO Box 7897, Riyadh 11159 Tel: 01-477-7714 x 6747 Fax: 01-477-6743 x 6743	Director:	Rizq Allah Assiri, MD
Central Region King Khalid University Hospital PO Box 2925, Riyadh 11461 Tel: 01-467-9488/2398 Fax: 01-467-9487	Director:	Dahish Ajarim, MD
Eastern Region King Fahd Hospital of the University PO Box 40004, Al Khobar 31952 Tel: 03-896-6741 Fax: 03-869-6741	Director:	Prof. Hassan Al Iddrissi, MD
King Abdulaziz University Hospital Faculty of Medicine & Allied Science PO Box 80215, Jeddah 21589 Tel: 02-624-0000 x 18244/18253 Fax: 02-617-1412	Director:	Mohamoud Shaheen Al Ahwal, MD
King Faisal Specialist Hospital & Research Center MBC-64 PO Box 3354, Riyadh 11211 Tel: 01-442-3938, 464-7272 x 24541	Directors:	Shouki Bazarbashi, MD Ali Al-Zahrani, MD, PhD

APPENDIX: B Continued....

Madinah & Northern Region

King Fahad Hospital
Madinah Al Monawarah
Tel: 04-486-1500 x 3760
Fax: 04-836-0951

Director:

Ahmed Tarawa, MD

National Guard Hospitals

King Abdulaziz Medical City (KKNHG)
PO Box 9515, Jeddah 21423
Tel: 02-624-0000 x 4085/4086
Fax: 02-624-0000 x 7242

Director:

Abdulwahab Andejani, MD

Security Forces Hospital

PO Box 3643, Riyadh 11481
Tel: 01-477-4480 x 1193
Fax: 01-476-4757, 01-477-4480 x 3184

Director:

Abdulaziz Saleh Aba Hussein, MD

Southern Region

King Khalid University
PO Box 641, Abha
Tel: 07-224-0711 / 224-7800 x 118
Fax: 07-224-0964 / 224-7570

Director:

Hassan Trabulsi, MD

Western Region

King Abdulaziz Hosp. & Oncology
Center
PO Box 31467, Jeddah 21497
Tel: 02-637-5555 x 2283/2200
Fax: 02-637-9811

Director:

Hasnah Al Ghamdi, MD

Edward De Vol, PhD

Director

January 2001 - April 2006

Hadir Meir, MD

Director

January 2001 - August 2005

Susan E. Young, CCHRA®, CTR

**Administrative
Director**

March 2003 -May 2006

APPENDIX C NCR Data Request Form

**National Cancer Registry
Ministry of Health
Kingdom of Saudi Arabia**



**السجل الوطني للأورام
وزارة الصحة
المملكة العربية السعودية**

Request for data from the National Cancer Registry

All requests should be submitted to the attention of the Chairman of Directors, National Cancer Registry,
MCB 64, P.O. Box 3354, Riyadh 11211, Saudi Arabia, Fax: +966 1 442 3941

Name : _____
Department : _____
Hospital : _____
Telephone : _____

Date Submitted : _____

Information Requested:

(Specify Patient Population, Time Period, Year/s, Anatomic Site/Histology, Staging information, Region, etc.)

Purpose of Request:

(Specify Presentation at conference/meeting/publication, clinical/epidemiological study, personal information, etc.)

Collaborators and Co-authors:

Requesters affirmation statement:

I hereby, the requester of the above data affirm that the data given to me by the NCR will be treated with utmost confidentiality in relation to patient's identity. I also affirm that the data given to me will not be presented or published by me or any of my collaborators as an original work but rather can be cited in my presentations and/or publication with acknowledgment of the NCR.

Requesters Signature

Date

☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆☆

For Official use only:

Request : Approved ☐

Denied ☐

Chairman NCR Board of Directors Signature
Dr. Shouki Bazarbashi

Date

APPENDIX D Cancer Registration Abstract Form

*MUST REFER TO NCR OPERATING MANUAL

KINGDOM OF SAUDI ARABIA
MINISTRY OF HEALTH
NATIONAL CANCER REGISTRY
November 2002 (Updated)

1. ACCESSION DATE

d	d	m	m	y	y	y	y		

(Date Abstract Completed, by hand)

CANCER REGISTRATION ABSTRACT

NAME

2. FIRST (Must be filled)	3. FATHER	4. GRANDFATHER	5. FAMILY (Must be filled)

USE NCR ABBREVIATIONS LIST FOR NAMES, PART 11

6. SAUDI ID/ PASSPORT/ IQAMA NUMBER

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

7. Sex ☐

- 1-Male
2-Female
9-Unknown

8. DATE OF BIRTH

d	d	m	m	y	y	y	y		

(if only year is known, use 01/07/)

9. AGE AT DIAGNOSIS ☐ YEAR(S)

12. MARITAL STATUS ☐
1. Single
2. Married
3. Divorced
4. Widowed
5. Unknown

10. NATIONALITY ☐ Code ☐

11. Nationality Text

13. PERMANENT ADDRESS ☐ Code ☐

14. ADDRESS DETAILS

City:	
P.O. Box	Zip Code:

15. TELEPHONE NUMBER ☐

16. DATE OF DIAGNOSIS ☐ ☐ / ☐ ☐ / ☐ ☐ ☐ ☐ ☐ ☐

(First time physician states that patient has a malignancy Clinically or Pathologically)

17. TOPOGRAPHY ☐ Code ☐

18. Topography Text

19. MORPHOLOGY/ HISTOLOGY ☐ Code ☐

20. Morphology Text

21. BEHAVIOR ☐

2. Insitu
3. Malignant/Invasive

22. GRADE ☐

1. Well differentiated/
Differentiated, NOS
2. Moderately differentiated/
Moderately well differentiated
3. Poorly differentiated
4. Undifferentiated / Anaplastic
5. T-cell
6. B-cell/Pre-B/B-precursor
7. Null cell/Non-T-Non-B (for Leukemias only)
8. Natural killer cell
9. Unknown

23. SEER SUMMARY STAGE (EXTENT) ☐

1. In situ
2. Localized
3. Regional by direct extent
4. Regional by lymph node
5. Regional (both 3 and 4)
6. Regional, NOS
7. Distant Metastasis/Systematic Disease
9. Unknown

25. BASIS OF DIAGNOSIS ☐

0. DCO (Death certificate only)
1. Clinical
2. Radiology
3. Surgery
4. Lab test
5. Cytology/Hematology
6. Histology of Metastasis
7. Histology of Primary
8. Histology, NOS
9. Unknown

Details if any:

26. REPORTING HOSPITAL ☐ Code ☐

27. Reporting Hospital Text

28. MEDICAL RECORD NO. ☐

29. PATHOLOGY SPECIMEN NO. ☐

30. LAST CONTACT ☐ ☐ / ☐ ☐ / ☐ ☐ ☐ ☐ ☐ ☐

31. STATUS ☐

1. Dead
2. Alive
9. Unknown

32. CAUSE OF DEATH ☐

1. Cancer
2. Other
3. Not Applicable
9. Unknown

33. CanReg-4 NO. (Computer Assigned) ☐

34. CODER ID # ☐

35. DATA ENTRY ID # ☐

SIGNATURE: _____

